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Abstract
Since their discovery over two decades ago, the molecular and cellular functions of
the Nipsnap family of proteins (Nipsnaps) have remained elusive until recently. Nipsnaps
interact with a variety of mitochondrial and cytoplasmic proteins. They have been
implicated in multiple cellular processes and associated with different physiologic and
pathologic conditions, including pain transmission, Parkinson’s disease, and cancer.
Recent evidence demonstrated a direct role for Nipsnap1 and Nipsnap2 proteins in
regulation of mitophagy, a process that is critical for cellular health and maintenance. Our
group has previously reported an interaction between Nipsnap1 and the Alzheimer’s
disease amyloid precursor protein. In addition, Nipsnap1 binds to pyruvate dehydrogenase
(PDH), which controls the critical step of converting pyruvate to acetyl-CoA and connects
cytosolic glycolysis to mitochondrial TCA cycle. Importantly, Nipsnaps contain a 110
amino acid domain that is evolutionary conserved from mammals to bacteria. However,
the molecular function of the conserved Nipsnap domain and its potential role in mitophagy
and regulation of mitochondria have not been explored. Recently, using protein structure
modeling and virtual ligand screening, our group identified NAD and NADP as potential
ligands for the conserved Nipsnap1 domain.
The goal of my studies was to investigate the physiological function of Nipsnap1
interaction with PDH and potential ligands such as NAD, NADP and ATP. In the first
study, we show that Nipsnap1 deficiency does not have a significant effect on PDH protein
level nor PDH enzyme activity in the brain and liver tissues of Nipsnap1 knock-down mice.
In addition, overexpression of Nipsnap1 did not change PDH enzyme activity in HEK293
cells. This study suggests that Nipsnap1 may bind to PDH, possibly for targeting its
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localization, but does not affect PDH enzyme activity. In the second study, we show that
the highly conserved C-terminal region of Nipsnap1 directly binds to NAD, NADP and
ATP. These interactions were confirmed using in vitro biochemical binding assays. In
addition, using site-directed mutagenesis, we show that Nipsnap1 interaction with NAD
and ATP requires specific amino acid residues corresponding to a binding pocket within
its conserved C-terminal domain. Dual binding of NAD and ATP to the same binding
pocket is unusual. However, it raises an intriguing possibility that the highly conserved
Nipsnap domain interacts with a substrate that is ubiquitously present across all species
and that it might act as a sensor for mitochondrial health.
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Preface
Two manuscripts and one conference abstract were prepared from this study. The
conference abstract was published in Alzheimer's & Dementia: The Journal of the
Alzheimer's Association, 2018. One review paper was published in BioEssays, 2021. One
manuscript was prepared based on the results of Chapter III and is being submitted to a
peer-reviewed journal. The manuscripts details are mentioned below.
•

Fathi E, Yarbro JM, Homayouni R. (2021) “NIPSNAP protein family emerges as
a sensor of mitochondrial health.” BioEssays. DOI: 10.1002/bies.202100014.

•

Yarbro JM, Fathi E, Ziebarth JD, Gacasan SB, Baker DL, Parrill A, Homayouni
R. (2018) “Characterization of APP and NAD(P)H interactions with NIPSANP1, a
novel mitochondrial protein”. Alzheimer's & Dementia: The Journal of the
Alzheimer's Association. 14 (7).

•

Fathi E, Yarbro JM, Ziebarth JD, Gacasan S, Qiao S, Wang Y, Parrill A, Graham
S, Homayouni R. (2021) “Direct binding of NAD(P)H and ATP to the highly
conserved C-terminal domain of Nipsnap1” (In submission).
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Chapter I: Introduction
Alzheimer’s Diseases
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most
prevalent form of dementia all over the world (Liu et al. 2019; Reitz, Brayne, and Mayeux
2011). AD starts with memory impairment and eventually leads to the decline in cognitive
function and activities of daily life (Liu et al. 2019; Wilson et al. 2012). In 2020,
approximately 5.8 million Americans and 50 million people worldwide of all ages are
believed to be living with AD (alzheimer.org). AD can be categorized into two major types:
early onset AD (also called familial AD) and late onset AD (also called sporadic AD)
(Armstrong 2019; Toyota et al. 2007). Early onset AD patients, accounting for about 5%
of all AD cases, develop symptoms prior to age of 65 (Armstrong 2019; Toyota et al. 2007).

Pathological hallmarks of AD include accumulation of hyperphosphorylated tau
associated with neurofibrillary tangles inside the neuron, formation of β-amyloid (Aβ)
plaques outside of neurons, loss of synapses, neural death, and chronic inflammation
(Clarke et al. 2018; Reitz et al. 2011). Mutations in presenilins 1 & 2 and amyloid precursor
protein (APP) lead to abnormal cleavage of APP and formation of Aβ and APP intracellular
domain (AICD) (Park et al. 2009). In addition, the initial cause of neuronal death in
sporadic AD may involve alterations in oxidative phosphorylation, bioenergetics and
energy pathways (Armstrong 2019; Jové et al. 2014; Sun, Youle, and Finkel 2016;
Trushina et al. 2013).
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Amyloid precursor protein
Amyloid precursor protein (APP) belongs to a highly conserved family of proteins
including the amyloid precursor-like proteins (APLP1 and APLP2). All APP family
members are single-pass transmembrane proteins, with a highly conserved cytoplasmic Cterminal domain and a large and variable extracellular domain (O’Brien and Wong 2011;
Zhang et al. 2011). Accumulating evidence suggests that APP family proteins play critical
roles during developing and mature brain by promoting cell growth, neurite outgrowth,
motility, cell survival and apoptosis, which is modulated by soluble ectodomain produced
from APP cleavage (O’Brien and Wong 2011; Steubler et al. 2021).
APP can undergo non-amyloidogenic pathway mediated by α-secretase and γsecretase, and amyloidogenic pathway processed by β-secretase and γ-secretase. APP
primarily is cleaved by α-secretase and γ-secretase resulting in the generation of
ectodomain APPS-α, a soluble fragment, and an intracellular C-terminal fragment (AICD)
(Bukhari et al. 2017; O’Brien and Wong 2011). Mutations in APP, PSEN1 and PSEN2
genes lead to abnormal cleavage of this protein by β-secretase and γ-secretase releasing
40-42 amino acid fragments known as Aβ which tend to aggregate and form Aβ plaques
outside of neurons (Armstrong 2019; O’Brien and Wong 2011).
The C-terminal part of APP which has a highly conserved domain is essential for APP
function (Bukhari et al. 2017). AICD interacts with different proteins, and induces
important changes in gene expression and apoptosis, which suggest that AICD may be
involved in AD signaling pathology (Bukhari et al. 2017; Kim et al. 2003). It has been
shown that AICD upregulated glycogen synthase kinase 3β (GSK-3β) expression leading
to neuronal death in in rat primary cortical neurons (Kim et al. 2003). In addition, AICD
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increased hyperphosphorylation of tau, which is a hallmark of AD pathology (Kim et al.
2003). Recently, a study showed that increased AICD production attenuates neuron in CA1
region of hippocampus firing and disrupts spatial memory task (Pousinha et al.
2019).Therefore identifying the AICD interacting proteins may provide a better
understanding of pathophysiological functions of APP and its role in AD.

Nipsnap1 interacts with APP
Using a functional proteomic approach, our laboratory showed that AICD interacts
with mitochondrial creatine kinase and a novel protein

called protein 4-

nitrophenylphosphatase domain and non-neuronal SNAP25-like homolog 1 (Nipsnap1)
(Tummala, Li, and Homayouni 2010). A synthetic peptide (15 amino acids) corresponding
to conserved domain of AICD or a control peptide with same 15 amino acids but scrambled
sequence were cross-linked to an agarose resin for affinity chromatography. Mouse brain
lysate was passed through this affinity chromatography column and the bound proteins
were eluted, separated using sodium dodecylsulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and visualized by silver staining. A ~30 kDa interacting protein was
sequenced using mass spectrometry followed by search through NCBI protein database
and was identified as Nipsnap1 (NM_008698) (Tummala et al. 2010). In this study, APP
interaction with Nipsnap1 protein was confirmed both in mouse brain lysate and in
transiently transfected COS7 cells with Nipsnap1 and APP. In addition, APP cotransfection decreased Nipsnap1 mitochondrial localization and protein levels in cells
(Tummala et al. 2010).

3

Overview of Nipsnap1
The name Nipsnap (4-nitrophenyl phosphatase and non-neuronal SNAP25 like
protein homolog) is somewhat misleading because the protein contains neither a
phosphatase nor a SNAP25 like domain. This name was assigned based on the initial
discovery of the gene in C. elegans, apparently in an operon, adjacent to two other genes:
one that is similar to yeast nitrophenyl phosphatase (NIP) and the other to mouse
synaptosomal associated protein 25 (SNAP25) (Figure1) (Seroussi et al. 1998). SNAP25
is part of the SNARE complex, which is involved in vesicle transport, (Tsui and Banfield
2000) and hence for many years Nipsnaps were assumed to be involved in vesicle
trafficking. However, definitive evidence from multiple groups have shown that Nipsnaps
are targeted to the mitochondria (Nautiyal 2008; Nautiyal et al. 2010; Princely Abudu et
al. 2019; Tummala et al. 2010; Verhagen et al. 2007) and more recent evidence has shown
that Nipsnap1 and Nipsnap2 directly regulate mitophagy. Here, I will summarize the body
of knowledge about Nipsnaps and draw attention to the highly conserved Nipsnap domain
that has yet to be investigated.
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Figure 1 Nipsnap1 gene structure in C. elegans. The Nipsnap1 gene (K02D10.1), including 4 exons, is flanked by two distinct
genes. The upstream gene is similar to yeast nitrophenyl phosphatase (NIP, K02D10.3) and the downstream gene is similar to
mouse synaptosomal associated protein 25 (SNAP29). UCSC C. elegans assembly 2013 (WBcel235/ce11).
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The Nipsnap domain is highly conserved throughout evolution
In contrast to C. elegans, which has only one Nipsnap gene with four exons, there
are four distinct Nipsnap genes with varying number of exons in humans. Both human
NIPSNAP1 and NIPSNAP2 genes contain 10 exons and are located on chromosomes 22q12
and 7p12, respectively. In contrast, NIPSNAP3B (encoding NIPSNAP3 protein) and
NIPSNAP3A (encoding NIPSNAP4 protein) contain 6 exons and are tandemly located on
chromosome 9q31 (Lee, Zareei, and Daefler 2002; Qiu et al. 2001; Seroussi et al. 1998;
Wang et al. 1998). NIPSNAP1 and NIPSNAP2 genes were identified concurrently in 1998
by different groups; NIPSNAP1 was discovered as part of the human genome sequencing
of chromosome 22 while NIPSNAP2 was identified as an upregulated gene in glioblastoma
(Seroussi et al. 1998; Wang et al. 1998). In 2001, human NIPSNAP3B (a.k.a NIPSNAP3)
and NIPSNAP3A (a.k.a NIPSNAP4) genes were identified in proximity to ATP-binding
cassette transporter A1 (ABCA1) gene on chromosome 9q31 (Qiu et al. 2001). Another
group, using a yeast two hybrid approach, identified Nipsnap 4 as a host cell target for
SpiC, which is a Salmonella virulence protein (Lee et al. 2002). At that time, because SpiC
was the only known role for Nipsnap4, it was named Target for Salmonella Secreted
protein C (TassC). The human NIPSNAP genes and their protein products have multiple
aliases, and so for clarity we will refer to the Nipsnap family protein members as Nipsnap
1, Nipsnap 2 (instead of GBAS), Nipsnap 3 (instead of NIPSNAP3B) and Nipsnap 4
(instead of NIPSNAP3A and TassC).
As the structural organization of the genes suggest, NIPSNAP1 and NIPSNAP2
encode highly similar proteins containing 284 and 286 amino acids with 67.7% sequence
identity. In contrast, NIPSNAP3 and NIPSNAP4 genes each encode 247 amino acid
6

containing proteins with 87.0% sequence identity (Lee et al. 2002; Mathai 2018; Nautiyal
2008). Surprisingly, there is only 14.3% sequence identity across all four proteins. All four
NIPSNAPs contain an approximately 100 amino acid domain (called the ‘NIPSNAP
domain’) that is highly conserved throughout evolution, present in 2241 species to date
according to Pfam database (Figure 2a). Notably, NIPSNAP1 and NIPSNAP2 proteins
contain only one NIPSNAP domain, whereas NIPSNAP3 and NIPSNAP4 contain two
tandem NIPSNAP domains (Figure 2b). The high degree of similarity in gene structure,
protein domain organization and amino acid sequence between NIPSNAP1 and
NIPSNAP2 suggest that they may have redundant functions that are distinct from
NIPSNAP3 and NIPSNAP4 (Mathai 2018; Princely Abudu et al. 2019).
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Figure 2 Evolutionary view of the NIPSNAP domain distribution across species. (A) Representation of NIPSNAP domain across
2241 species in pfam database. (B) NIPSNAP domain architecture across human NIPSNAP family. NIPSNAP3 (NIPSNAP3B)
and NIPSNAP4 (NIPSNAP3A) contain two tandem NIPSNAP domains whereas NIPSNAP1 and NIPSNAP2 contain one
NIPSNAP domain. Data obtained from http://pfam.xfam.org/family/NIPSNAP#tabview=tab7 in July 2020.
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NIPSNAPs have distinct tissue expression patterns
NIPSNAP genes exhibit widespread and variable tissue expression. According to
Genotype-Tissue Expression (GTEx) Portal, a publicly available RNA expression
database, NIPSNAP1 is highly expressed in liver, kidney, adrenal gland, and brain (Figure
3). In contrast, NIPSNAP2 is highly expressed in skeletal muscle and Heart. In addition,
NIPSNAP2 has higher expression in adrenal gland and brain compared to NIPSNAP1. Both
NIPSNAP3 and NIPSNAP4 have lower levels of expression compared to NIPSNAP1 and
NIPSNAP2, and NIPSNAP4 displays a wider tissue distribution than NIPSNAP3.

Figure 3 Gene expression profile of NIPSNAP family genes. NIPSNAP1 is highly
expressed in brain, liver, kidney, and adrenal gland while NIPSNAP2 is highly expressed
in skeletal muscle, heart, brain and adrenal gland. NIPSNAP3A and NIPSNAP3B have
similar tissue expression however NIPSNAP3B expression is not as strong as
NIPSNAP3A. Data obtained from Genotype-Tissue Expression (GTEx) Portal
(https://www.gtexportal.org/) on 08/18/2020.
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Consistent with its transcript levels, immunoblot experiments have shown that the
mouse Nipsnap1 protein is highly expressed in liver, kidney and brain, and to a lesser
degree in skeletal muscle (Nautiyal et al. 2010; Okuda-Ashitaka et al. 2012; Princely
Abudu et al. 2019; Schoeber et al. 2008; Seroussi et al. 1998; Tummala et al. 2010).
Nipsnap2 protein is predominantly expressed in skeletal muscle, heart and brain
(Martherus et al. 2010; Seroussi et al. 1998; Wang et al. 1998). While Nipsnap3 and
Nipsnap4 show mostly similar tissue expression patterns, including high expression in
brain and testis, Nipsnap3 protein level is much higher in skeletal muscle compared to
Nipsnap4 (Buechler et al. 2004).
In 2002, Satoh et al. reported the presence of Nipsnap1 in postsynaptic density
(PSD) fraction of synapses isolated from mouse forebrains, suggesting that Nipsnap1 may
play a role in modulation of synaptic activity and possibly learning and memory (Lüscher
et al. 2000). Others have also identified Nipsnap1 in synaptic membrane preparations from
mouse brain (Okuda-Ashitaka et al. 2012). In 2010, Nautiyal et al. showed that Nipsnap1
is exclusively expressed in neurons of rat brains using immunofluorescence and
immunohistochemistry assays (Nautiyal et al. 2010). They showed that Nipsnap1 is widely
expressed in neurons throughout various brain structures, including cerebral cortex
(pyramidal neurons), cerebellum (Purkinje neurons), hippocampus, brain stem
(noradrenergic neurons), spinal cord (motor neurons) and midbrain (dopaminergic
neurons) (Nautiyal et al. 2010).
Analysis of the primary amino acid sequence of Nipsnaps revealed that all four
family members have an N-terminal mitochondrial targeting sequence (MTS) (Nautiyal
2008). Moreover, mitochondrial localization of all four Nipsnaps was experimentally
10

shown by several different groups (Nautiyal 2008; Nautiyal et al. 2010; Princely Abudu et
al. 2019; Tummala et al. 2010; Verhagen et al. 2007). In 2010, Nautiyal et al. and Tummala
et al. separately showed that Nipsnap1 localizes to the mitochondria via its N-terminal
MTS. These results were consistent with the previous identification of Nipsnap1 in
mitochondrial fractions (Mootha et al. 2003). In 2017, another group reported Nipsnap1
and Nipsnap2 localize to both the outer and inner mitochondrial membranes (Yamamoto,
Okamoto, et al. 2017). Extraction of Nipsnap1 and Nipsnap2 with alkaline sodium
carbonate suggested that they are mitochondrial matrix proteins and not membrane
integrated proteins. Recently, another group confirmed that Nipsnap1 and Nipsnap2 target
mitochondria using two different MTS’s (Princely Abudu et al. 2019). The first MTS
appears to import Nipsnap1 and Nipsnap2 into mitochondria, and the second MTS recruits
them to the outer mitochondrial membrane upon mitochondrial depolarization.

Nipsnap interacting proteins
Since their discovery in the 1990’s, Nipsnap proteins have been shown to interact
with a wide range of mitochondrial and cytosolic proteins (summarized in Table 1). Most
of the interaction studies were performed on Nipsnap1 and Nipsnap2 proteins. In general,
Nipsnap1 mostly interacts with mitochondrial proteins including Pyruvate Dehydrogenase
Complex (PDC), Branched chain α-keto acid (BCKA) dehydrogenase, TOMM20, and
HSP60. Nipsnap1 also interacts with non-mitochondrial proteins including membrane
channel protein TPRV5/6, neuropeptide Nocistatin (NST) and Bone Morphogenetic
Protein (BMP). Moreover, Nipsnap1 also interacts with different compounds such as
11

Trichostatin A, Clarithromycin, Umbelliprenin, Finasteride and Dutasteride. Most
importantly, Nipsnap1 and Nipsnap2 interact with proteins involved in autophagy and
mitophagy such as Autophagy-related protein 8 (ATG8), LC3/GABARAP, ALFY, P62,
NBR1, NDP52 and TAX1BP1. In contrast to Nipsnap1 and Nipsnap2, limited information
has been reported about Nipsnap3 and Nipsnap4 interacting proteins. Only one study has
shown a direct interaction of Nipsnap3 or Nipsnap4 with Inhibitor of Apoptosis Protein
(IAP) (Verhagen et al. 2007). Altogether, Nipsnap proteins interact with a wide variety of
mitochondrial proteins, particularly with proteins that are involved in mitophagy and
apoptosis. It is important to note, however, that very few of the above studies have mapped
the precise interaction domains in Nipsnap proteins, and none of the interactions described
to date have been mapped to the highly conserved Nipsnap domain.
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Table 1 Comprehensive list of Nipsnap interacting proteins.
Protein
Function(s)
Nipsnap1 Interacting proteins and compounds
APP intracellular domain
(AICD)

Tissue/cell

Reference

In vitro/COS7 cells and
mouse brain

(Tummala et al. 2010)

PDC (E2 subunit)

In vitro

(Nautiyal et al. 2010)

BCKA dehydrogenase

In situ/ CHO cell lines

(Islam et al. 2010)

BCKA dehydrogenase (E2
subunit)
Nocistatin (NST)

In vitro

(Nautiyal et al. 2010)

In vitro/COS7 cells and
mice
In vitro/ HEK293 cells

(Okuda-Ashitaka et al.
2012)
(Schoeber et al. 2008)

Xenopus
Xenopus

(Day and Beck 2011;
Peiffer et al. 2005)
(Day and Beck 2011)

In vitro/ hepatoma cell lines

(Chiba et al. 2004)

In vitro/ QU-DB cells

(Khaghanzadeh et al.
2016)
(Soskic and Schrattenholz
2005)
(He et al. 2007)

TRPV5/6
Bone Morphogenetic
Proteins (BMP)
BMP

Involved in pain
transmission
Inhibits TRPV5/6
channel activity

Associated with lens
generation

Trichostatin A
Umbelliprenin

Anti-tumor activity

Finasteride and dutasteride

Neuroprotective role

Mitochondrial DNA
(mtDNA)

mtDNA maintenance

In vitro
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Table 1 (Continued)
Nipsnap2 interacting proteins
Cyclophilin-D

Involved in
mitochondrial
permeability transition
pore
Nipsnap1 and Nipsnap2 interacting proteins
Autophagy-related protein Autophagy regulator
8 (ATG8),
LC3/GABARAP
Human ATG8
Autophagy regulator

In vitro

(Leung, Varanyuwatana,
and Halestrap 2008)

In vitro/U2OS cells

(Behrends et al. 2010)

In vitro/U2OS cells

ALFY (autophagy
adaptor)
P62 (autophagy receptor)

Mediates mitophagy

NBR1 (autophagy
receptor)
NDP52 (autophagy
receptor)
TAX1BP1 (autophagy
receptor)
HSP60

Mediates mitophagy

Mice, In vitro/U2OS, MEF
and Hella cells
In vitro/U2OS, HEK293,
MEF and Hella cells
In vitro/Hela cells

Mediates mitophagy

In vitro/Hela cells

Mediates mitophagy

In vitro/Hela cells

P62/SQSTM1

Involved in immune
signaling, protein
degradation,
autophagy, and stress
responses

(Princely Abudu et al.
2019)
(Princely Abudu et al.
2019)
(Princely Abudu et al.
2019)
(Princely Abudu et al.
2019)
(Princely Abudu et al.
2019)
(Princely Abudu et al.
2019)
(Yamamoto, Okamoto, et
al. 2017)
(Yamamoto, Okamoto, et
al. 2017)

Mediates mitophagy

In vitro/BEAS-2B cells
In vitro/BEAS-2B cells
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Table 1 (Continued)
Clarithromycin

Immune system

In vitro/BEAS-2B and T24
cells

(Yamamoto, Ogasawara,
et al. 2017)

Nipsnap4 Interacting Proteins
SpiC (Salmonella
Yeast two-hybrid
virulence protein)
X-linked Inhibitor of
Acts as antagonists and In vitro/ HEK293 cells
Apoptosis Protein (XIAP) induces apoptosis
Nipsnap3 and Nipsnap4 interacting proteins
Inhibitor of apoptosis
Acts as antagonists and In vitro/ HEK293 cells
protein (IAP)
induces apoptosis
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(Lee et al. 2002)
(Verhagen et al. 2007)

(Verhagen et al. 2007)

Nipsnap1 and Nipsnap2 trigger mitophagy
Mitophagy is a selective form of autophagy that degrades dysfunctional
mitochondria. It is vital for retention of cellular homeostasis, especially in postmitotic
neural cells (Lemasters 2005). Mitochondria accrue damage through oxidative
phosphorylation and generation of reactive oxygen specious (ROS) (Wallace 2013).
Therefore, turnover of defective and aged mitochondria is required to sustain the integrity
of cells. Disruption in mitophagy has different effects in aging, development,
neurodegenerative diseases and cancer (Williams and Ding 2018). One of the well
characterized mitophagy pathways involves PTEN-induced kinase 1 (PINK1) and PRKN
pathway (Chan et al. 2011; Lazarou et al. 2015; Pickrell and Youle 2015). PINK1 colocalizes on the surface of dysfunctional mitochondria, phosphorylates and activates E3
ubiquitin ligase PARKIN, and recruits PARKIN to the damaged mitochondria. PARKIN
amplifies ubiquitin on the surface of mitochondria and triggers selective autophagy.
Autophagy/mitophagy receptors contain a LC3-interacting region (LIR) binding to
light chain 3 (LC3) and GABA type A receptor-associated protein (GABARAP)
(Birgisdottir, Lamark, and Johansen 2013; Pankiv et al. 2007). ATG8 is a key factor in
autophagy and consists of six LC3/GABARAP subfamilies in human. Interestingly in
proteomic studies, Nipsnap1 and Nipsnap2 were identified as negative regulators of ATG8
network, which interact with LC3/GABARAP (Behrends et al. 2010; Rigbolt et al. 2014).
Furthermore, another group showed that Nipsnap1 interacts with the autophagy receptor
sequestosome 1 (SQSTM1 or p62), which regulates cell proliferation, survival or death
through autophagy (Yamamoto, Okamoto, et al. 2017). In a recent study, Abudu et al.,
(2019) demonstrated that Nipsnap1 and Nipsnap2 recruit autophagy proteins on the
16

mitochondrial outer membrane. Depolarization of damaged mitochondria leads to
translocation of Nipsnap1 and Nipsnap2 to the outer mitochondrial membrane, where they
bind to P62 and ALFY to recruit ATG8 and other autophagy proteins to the surface of
damaged mitochondria (Abudu et al. 2019; Liu et al. 2019; Mukherjee and Dikic 2019).
Moreover, Abudu and colleagues found that Nipsnap1 and Nipsnap2 have redundant
functions, where Nipsnap1 can compensate for the absence of Nipsnap2 in PINK1-PRKN
mediated mitophagy (Princely Abudu et al. 2019).

Nipsnaps regulate apoptosis
Early studies showed that Nipsnap1 is involved in suppression of transient receptor
potential vanilloid channel 6 (TRPV6), which regulates Ca2+ entry into cells (Schoeber et
al. 2008). Inhibition of TRPV6 activity by Nipsnap1 led to promotion of apoptosis, which
suggests that Nipsnap1 may have a tumor suppressor role (Schoeber et al. 2008). In 2007,
Verhagen and colleagues (Verhagen et al. 2007) showed that Nipsnap3 and Nipsnap4 bind
to Inhibitor of Apoptosis Protein (IAP), which regulate apoptosis, cell proliferation, cell
migration and inflammation (Berthelet and Dubrez 2013). They showed that cleavage of
the N-terminal mitochondrial targeting sequence in Nipsnap4 exposed an IAP binding
motif (IBM). IBM interaction with the baculoviral IAP repeat (BIR) 2 domain of IAP
interfered with its ability to inhibit Caspase activity and to suppress apoptosis (Verhagen
et al. 2007). Indeed, they showed that Nipsnap4 binding to IAP enhanced UV-induced
apoptosis (Verhagen et al. 2007). Interestingly, unlike Nipsnap4, the binding of Nipsnap1
and Nipsnap2 to IAP and their effect on apoptosis have not yet been examined.
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In 2008, Leung et al. showed that Nipsnap2 binds to cyclophilin-D, a key regulator
of the mitochondrial permeability transition (MPT) (Leung et al. 2008). Subsequently,
another group showed that depletion of Nipsnap2 (a.k.a GBAS) and Spastic Paraplegia 7
(SPG7) attenuated MPT in HEK293 cells (Shanmughapriya et al. 2015). Contradicting
these results, Klutho and colleagues showed that depletion of Nipsnap2 and SPG7 did not
have a significant effect on MPT induced by Ca2+ in primary mouse embryonic fibroblasts
(MEFs) (Klutho et al. 2020). While Shanmughapriya group utilized long-term reduction in
Nipsnap2 and SPG7 (by shRNA), Klutho group utilized an acute knockdown of Nipsnap2
and SPG7 (by siRNA) to rule out the compensantory changes due to chronic depletion of
Nipsnap2 and SPG7 (Klutho et al. 2020; Shanmughapriya et al. 2015). In addition, Klutho
and colleagues showed that knockdown or overexpression of Nipsnap2 did not affect ATP
levels in MEF cells. These contradicting results could be due to differences in cell lines
and functional compensation by Nipsnap1 (Klutho et al. 2020).

Nipsnap1 and Nipsnap2 modulate mitochondrial metabolism
Two different groups have shown that the E2 subunit of PDC interacts with
Nipsnap1 (Nautiyal et al. 2010; Princely Abudu et al. 2019). PDC is a mitochondrial
complex, consisting of three subunits E1, E2 and E3, that converts pyruvate to acetyl-CoA
and NADH. PDC connects cytosolic glycolysis to mitochondrial tricarboxylic acid cycle
(TCA) cycle and ultimately oxidative phosphorylation and ATP production. In addition to
PDC, Nipsnap1 binds to transacetylase of BCKA dehydrogenase, a multi-subunit enzyme
located in mitochondria, which is responsible for catabolism of branched chain amino acids
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(Islam et al. 2010). The interaction of Nipsnap1 with PDC and BCKA is supported by
previous reports that Nipsnap1 associates with a 100−120 kDa protein complex
(Reifschneider et al. 2006). However, the functional consequence of Nipsnap1 interaction
with PDC and BCKA has not been examined.
Metabolomic analysis by our group revealed that targeted knockdown of Nipsnap1 in mice
resulted in broad changes in fatty acid, nucleotide, and amino acid metabolic pathways. In
addition, Nipsnap1 deficiency increased the oxidative state in liver, as indicated by an
increase in cysteine–glutathione disulfide and a decrease in reduced glutathione (Ghoshal,
Jones, and Homayouni 2014). The broad effect of Nipsnap1 deficiency on metabolism is
reminiscent of the metabolomic changes observed in Sirtuin3 (SIRT3) knockout mice
(Dittenhafer-Reed et al. 2015; Hirschey et al. 2010, 2011; Meng et al. 2019). SIRT3 is an
NAD-dependent deacetylase localized in the mitochondrial matrix. SIRT3 regulates a
number of enzymes involved in TCA cycle, oxidative phosphorylation and fatty acid
oxidation (Dittenhafer-Reed et al. 2015; Hirschey et al. 2010). SIRT3 deficiency reduced
the level of fatty acid oxidation along with increased acetylation of long-chain acyl CoA
dehydrogenase (LCAD) and the E1 subunit of PDC, which result in reduced activity of
LCAD and PDC (Hirschey et al. 2010; Wei et al. 2019). Interestingly, quantitative
proteomics of lysine acetylation identified Nipsnap1 as one of the top 10 major targets of
SIRT3 (Rardin et al. 2013). All together, these data suggest that Nipsnap1 is involved in
regulation of mitochondrial metabolism, possibly through an interaction with PDC and
BCKA, and under the control of SIRT3.In contrast to Nipsnap1, very few studies
investigated the role of the other Nipsnap family members with respect to cellular
metabolism. Only one study has shown that Nipsnap2 depletion (by siRNA transfection)
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caused a substantial decrease in total celluar ATP levels in HeLa cells, suggesting
Nipsnap2 may be involved in oxidative phosphorylation (Martherus et al. 2010).

Nipsnaps modulate pain signaling
Nipsnap1 is highly expressed in the brain stem, a critical area of brain involved in
nociception, pain processing and coordination of signals between cerebellum, cerebrum,
and spinal cord (Napadow, Sclocco, and Henderson 2019; Nautiyal et al. 2010). Nipsnap1
interacts with neuropeptide NST, which plays a role in pain signaling pathway (OkudaAshitaka et al. 2012). Importantly, Nipsnap1 knockdown mice lacked inhibition of tactile
allodynia by NST. Nipsnap1-NST interaction appears to be necessary for the inhibition of
nociceptin/orphanin FQ-evoked allodynia by NST (Okuda-Ashitaka et al. 2012; OkudaAshitaka and Ito 2015). In presence of prostaglandin E2, a primary mediator of
inflammation, Nipsnap1 mRNA expression was increased through cAMP-protein kinase
A signaling pathway in isolated dorsal root ganglion cells (Okamoto et al. 2016). Nipsnap1
is involved in pathogenesis of inflammatory pain by regulating central sensitization
through activation of extracellular signal-regulated kinase (ERK).
Previous studies have indicated that mitochondria play an important role in chronic
pain, including inflammatory and neuropathic pain (Areti et al. 2016; Guo et al. 2013; Sui
et al. 2013). Major mitochondrial functions such as energy production, generation of
reactive oxygen species (ROS), Ca2+ homeostasis, mitochondrial permeability transition
pore and apoptotic pathway can have critical roles in inflammatory and neuropathic pain
(Facecchia et al. 2011). Dysfunction in each mitochondrial electron transport chain
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(mETC) complex can cause chronic pain evaluated by application of selective inhibitors of
mETC I-V (Joseph and Levine 2006).

Nipsnaps are associated with neurological disorders
NIPSNAP1 is specifically expressed in neurons of locus coeruleus in the brain stem
where degeneration occurs in idiopathic Parkinson’s Disease (PD), Alzheimer’s Diseases
(AD) and other neurodegenerative diseases (Nautiyal et al. 2010; O’Neil et al. 2007). PD
involves selective degradation of dopaminergic neurons in the substantia nigra. Neurons
vulnerable to neurodegeneration in PD endure a high degree of mitochondrial stress.(Ge,
Dawson, and Dawson 2020) The familial form of PD is associated with mutations in a
number of PARK genes including PINK1, which mediates mitochondrial quality control
(Lesage and Brice 2009; Pickrell and Youle 2015). Nipsnap1 deficient zebrafish exhibit
PD phenotypes such as loss of dopaminergic neurons, locomotion deficiency and elevated
oxidative stress levels in the brain (Abudu et al. 2019; Princely Abudu et al. 2019).
Downregulation of NIPSNAP1 was also observed in PD brains.(Fu and Fu 2015)
Moreover, treatment of neural SH-SY5Y cells with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a widely used agent that induces PD-like biochemical changes, caused
downregulation of Nipsnap1 (Choi, Song, and Park 2014). After mitochondrial
depolarization, Nipsnap1 and PINK1 are localized on the outer mitochondrial membrane,
where they recruit PARKIN and initiate mitophagy (Abudu et al. 2019; Pickrell and Youle
2015). These results indicate that Nipsnap1 could play an important role in Parkinson’s
pathogenesis through governing mitochondrial quality control.
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NIPSNAP1 is also highly expressed in the hippocampus, which is critical for
learning and memory, In addition hippocampus is one of the first brain structures that is
affected in AD (Jahn 2013; Nautiyal et al. 2010). Nipsnap1 was identified as a component
of PSD preparations from mouse brain (Satoh et al. 2002). PSD proteins play critical roles
in synaptic transmission and are affected during neurodegeneration (Vyas and
Montgomery 2016). In addition, mice treated with kainate, which induces seizure through
an increase in synaptic activity, showed increased Nipsnap1 levels in PSD fractions,
suggesting that Nipsnap1 may contribute to synaptic activity (Satoh et al. 2002). In a
different study, proteomics analysis of several AD brain regions showed significant
upregulation of Nipsnap2 in cortex and significant down regulation of Nipsnap2 in
substantia nigra (Zahid et al. 2014).
In vitro experiments by our group, using cultured cells and mouse brain lysates,
showed that Nipsnap1 interacts with APP intracellular domain (AICD) (Tummala et al.
2010). Growing evidence indicates that AICD contributes to AD pathophysiology
(Bredesen 2009; Ghosal et al. 2016; Müller et al. 2008; Pimplikar et al. 2010). One group
showed that non-glycosylated AICD and full-length APP aggregate in the mitochondrial
import channels in AD brains (Devi et al. 2006). In addition, others have shown that
mitophagy is compromised in AD, resulting in aggregation of dysfunctional mitochondria
(Cai and Jeong 2020; Kerr et al. 2017). The effect of AICD binding to Nipsnap1 on
mitophagy and its contribution to AD pathogenesis has not been investigated.
Other studies, using mouse models, suggest a potential role for Nipsnap1 in
neurological functions. Nipsnap1 expression was decreased in a mice model of
phenylketonuria, which exhibits cognitive deficits caused by defects in amino acid
22

metabolism (Nautiyal et al. 2010; Surendran, Tyring, and Matalon 2005). Another study
using heterozygous Xbp1 knockout mice revealed

that Nipsnap1 expression was

upregulated in pre-pulse inhibition, which is a measure of sensorimotor gating that is
deficient in patients with schizophrenia (Takata et al. 2010). All together, these studies
suggest that Nipsnap1 may play a role in a variety of neurological functions, presumably
through its modulation of mitophagy and mitochondrial metabolism. Further studies are
needed to directly test if Nipsnap1 plays a causative role in any neurological disorder.

Nipsnaps are associated with carcinogenesis
The intricate balance between cell proliferation and apoptosis is critical for carcinogenesis
(Wong 2011). Nipsnap1 was shown to inhibit TRPV6 activity, resulting in promotion of
apoptosis (Schoeber et al. 2008). TRPV6 is regarded as an oncochannel and upregulation
of TRPV6 has been associated with different cancers, including prostate, pancreas, breast
and ovarian adenocarcinomas (Stewart 2020). Chromosomal structural variation that
inactivated Nipsnap1, along with several other genes, is associated with malignant
metastatic cell lines derived from prostate epithelial cells (Malhotra et al. 2013). In a
different study, Nipsnap4 expression was significantly decreased in prostate cancer cells
in response to androgen treatment (Romanuik et al. 2009). Further support for an antitumor
role for Nipsnap1 is based on observations that Nipsnap1 is up-regulated in lung cancer
cells treated with umbelliprenin, a natural coumarin with anti-tumor activities
(Khaghanzadeh et al. 2016). In addition, treatment of hepatoma cell lines with Trichostatin
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A, a histone deacetylase inhibitor with anti-proliferative and anti-tumor activities through
the ERK pathway, upregulated Nipsnap1 expression (Chiba et al. 2004; Hsu et al. 2019).
It has been shown that Nipsnap2 overexpression is associated with increased
phosphorylation of CREB (Brittain et al. 2012). CREB overexpression is associated with
different types of cancer such as AML and non-small cell lung cancer (Sakamoto and Frank
2009). Wang and colleagues found Nipsnap2 is co-amplified with epidermal growth factor
receptor gene (EGFR) in several cancer cells lines (Wang et al. 1998). Recently, another
group showed that an intronic region of EGFR regulates Nipsnap2 expression and the rate
of survival of early-stage non-small cell lung cancer patients after surgery (Hong et al.
2018). This group observed that Nipsnap2 and EGFR expression levels were substantially
higher in lung tumors. Since Nipsnap2 expression is upregulated in different types of
cancer including lung, bladder, skin and breast cancer, Hong and coworkers suggested
Nipsnap2 could potentially be an oncogene (Hong et al. 2018; Matsumoto et al. 2016; PuigButille et al. 2017; Wang et al. 1998). Hong and colleagues indicated higher expression of
Nipsnap2 was substantially correlated with better rate of survival in lung and gastric
cancers and low rate of survival in ovarian and breast cancers (Hong et al. 2018). Therefore,
Nipsnap2 function in the pathogenesis of different cancer might be tissue and context
specific (Hong et al. 2018). Overexpression of Nipsnap2 enhanced the rate of centrosome
amplification, increased migration and invasiveness in bladder cancer cell lines, and was
associated with poor survival of patients with bladder cancer (Matsumoto et al. 2016).
The precise role of Nipsnaps in carcinogenesis is not clear. However, they may
exert anti-tumor effects through interactions with different proteins such as TRPV6 and
CREB. It is highly likely that the anti-tumor like properties of Nipsnaps are mediated
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through regulation of mitophagy. Accumulating evidence suggests that the balance
between mitochondrial biogenesis and mitophagy plays a critical role in carcinogenesis as
well as controlling cancer cell stemness, metabolic reprogramming, and resistance to
chemotherapy (Praharaj et al. 2020; Vara-Perez, Felipe-Abrio, and Agostinis 2019).

Nipsnaps modulate immune response
A genome-wide association study found a locus on 7p11.2 including Nipsnap2 gene
that substantially contributes in lipopolysaccharide (LPS)-induced fever (Ferguson et al.
2015). Disruption of Nipsnap1 and Nipsnap2 expression inhibited NF-κB activity and LPSinduced production of proinflammatory cytokines (IL-8 and IL-6) (Yamamoto,
Ogasawara, et al. 2017). In addition, proteome analysis showed Nipsnap1, Nipsnap2 and
very long-chain acyl-CoA dehydrogenase (VLCAD) bind to Clarithromycin (Yamamoto,
Ogasawara, et al. 2017). In this study, Clarithromycin inhibited NF-kB activity and
production of proinflammatory cytokines by interacting with Nipsnap1 and Nipsnap2.
Therefore, Nipsnap1 and Nipsnap2 may be involved in immune response induced by
Clarithromycin that suppresses NF-kB pathway and autophagy (Nakamura et al. 2010;
Yamamoto, Ogasawara, et al. 2017). Moreover, Nipsnap1 and Nipsnap2 interact with
P62/SQSTM1, which is a cytosolic scaffold protein involved in immune signaling, protein
degradation, autophagy and stress responses (Yamamoto, Okamoto, et al. 2017).
Squalene, a main component of olive oil, up-regulated Nipsnap1 mRNA expression
in microsomal fractions of apoE knockout mice, which are a well-known model of
atherogenesis (Ramírez-Torres et al. 2012). Silencing of NIPSNAP3 and NIPSNAP4 in
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human umbilical vein endothelial cells, significantly upregulated Von Willebrand Factor
(VWF), a carrier for Factor VIII (FVIII). FVIII and VWF are involved in hemorrhagic
disorders and risk of arterial and venous thrombosis (Sabater-Lleal et al. 2019). Moreover,
proteome analysis revealed that NIPSNAP4 expression is altered in CD4+ T cells of allergic
compared to non-allergic individuals (Blüggel et al. 2011).
In summary, insights into the molecular and cellular functions of Nipsnap family
proteins are slowly emerging. Recent evidence that Nipsnap1 and Nipsnap2 are critical
mediators of mitophagy is significant because it can generally explain their role in many
of the seemingly disparate physiological or pathological associations that have been
documented during the past two decades. It is not clear if mitophagy is the only role for
Nipsnap proteins or if they have other critical functions by virtue of their interaction with
PDC and BCKA complexes.
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Project goals
As mentioned above, Nipsnap1 interacts with E2 subunit of PDC which has a vital
role in connecting cytosolic glycolysis pathway to mitochondrial TCA cycle (Nautiyal et
al. 2010). However, the functional consequence of this interaction is not yet clear. In
addition, while Nipsnap1 has been implicated to have a significant part in PINK1-PRKN
mediated mitophagy (Princely Abudu et al. 2019), the exact mechanism by which
Nipsnap1 senses mitochondrial damage and triggers mitophagy is not completely
understood. It has been shown that NAD+/NADH ratio determines mitochondrial health
(Hwang and Hwang 2017). Increased level of NAD+ improves mitochondrial quality
through restoring mitophagy and elimination of damaged mitochondria (Fang et al. 2019;
Hwang and Hwang 2017). Preliminary work in our lab based on structure modeling and
virtual ligand screening has suggested that the highly conserved C-terminal domain of
Nipsnap1 binds to NAD(P)H (Yarbro 2018; Yarbro et al. 2018).
The overall goal of my dissertation project was to provide new insights into the
functional consequences of Nipsnap1 interaction with PDH and to investigate the
molecular role of the highly conserved C-terminal domain of NIPSNSP1 by addressing the
following questions: 1) Does Nipsnap1 deficiency affect pyruvate dehydrogenase (PDH)
levels or enzyme activity? 2) Does Nipsnap1 interact with NAD and other adenine
nucleotides? 3) Are these interactions direct or indirect? What domain of Nipsnap1 is
involved in these interactions? What amino acid residues are responsible for these
interactions?
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Chapter II: Regulation of pyruvate dehydrogenase complex activity by Nipsnap1
1. Introduction
Mitochondria are imperative organelles in neurons due to their role in generation
of ATP, reactive oxygen species, and control of apoptosis (Keating 2008). Studies have
shown that dysregulation of mitochondrial function is involved in neurodegenerative
disorders such as AD, PD, Huntington’s disease and amyotrophic lateral sclerosis (Lin and
Beal 2006; Mattson and Magnus 2006; Schon and Przedborski 2011). In fact, late onset
AD is associated with altered bioenergetic profiles, impaired mitochondrial metabolism
including distribution in activity of TCA cycle, and reduction in metabolism of NAD
(Sonntag et al. 2017).
Sheu et al., showed that activity of pyruvate dehydrogenase (PDH) complex is
reduced by 30% in cortex of AD patients compared to controls (Sheu et al. 1985). Another
study showed that overexpression of BACE1 (β-secretase which is responsible for
generation of Aβ peptide and AICD from APP) results in significant decrease in PDH
enzyme activity in SH-SY5Y cells (Findlay, Hamilton, and Ashford 2015). PDH complex
is a mitochondrial complex that consists of three subunits E1, E2, and E3, which converts
pyruvate to acetyl-CoA and NADH, connecting the cytosolic glycolysis pathway to
mitochondrial TCA cycle and ultimately oxidative phosphorylation and production of ATP
(Harris et al. 2002). PDH complex activity is regulated by direct feedback of allosteric
effectors such as acetyl-CoA and NADH and by covalent modification of pyruvate
dehydrogenase kinase (PDK) and pyruvate dehydrogenase phosphatase (PDP) (Harris et
al. 2002).
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Recently, two different research groups have shown that the E2 subunit of PDH
complex interacts with Nipsnap1 (Nautiyal et al. 2010; Princely Abudu et al. 2019). Our
group has shown that Nipsnap1 binds to the intracellular domain of APP (AICD) (Tummala
et al. 2010). In addition, our group has shown that Nipsnap1 deficiency causes major
metabolic changes in the liver, including alterations in lipid, nucleotide, carbohydrate, and
amino acid metabolism pathways (Ghoshal et al. 2014). Based on these results, we
hypothesized that some of the metabolic changes observed in AD may be due to AICDinduced disruption of PDH, possibly through a direct interaction with Nipsnap1. To address
this hypothesis, I aimed to:
1) Investigate if overexpression of APP-C31 could affect PDH enzyme activity in HEK
293 cells. 2) Study if Nipsnap1 overexpression influences PDH enzyme activity in
HEK293 cells. 3) Identify if Nipsnap1 deficiency affects PDH level. 4) Investigate if
Nipsnap1 deficiency changes PDH enzyme activity.
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2. Methods
PDH enzyme activity assays
To measure PDH enzyme activity, I used two different PDH enzyme assay kits.
1) Abcam dipstick PDH enzyme activity assay kit (#ab109882). This kit is an ELISA
based coupled enzyme reaction, which provides an approach to quantify the activity
of the PDH enzyme. On a defined area of the dipstick, PDH antibody is
immobilized. This defined area captures PDH enzymes migrating up from samples
which are placed in 96-well. PDH converts NAD to NADH which leads to
reduction of NBT, an insoluble colored precipitate measurable at 562 nm. The
intensity of the band is proportional to the amount of PDH activity that is
immobilized on the dipstick by the anti-PDH antibody.
2) Sigma colorimetric PDH activity assay kit (#MAK183). This kit provides a direct
procedure for measuring PDH enzyme activity. Like the dipstick PDH assay kit,
this kit uses a coupled enzyme reaction. However, instead of using immobilized
antibody and doing assay on dipstick, the reaction is done in solution. In addition,
the colorimetric product in this kit is measured by spectrophotometer at 450 nm and
it is proportional to the current PDH enzymatic activity. In this assay one unit of
PDH is equal to the amount of this enzyme which produces 1 µmole of NADH per
minute at 37 °C.
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Abcam lateral-flow dipstick PDH activity assay
To generate a standard curve for Abcam PDH kit, I used different protein amounts
extracted from HEK293 cells lysed in PDH lysis buffer. Protein concentration was
measured using the Pierce™ BCA protein assay kit (#23225) according to manufacturer
protocol. I used 40, 60, 80, 100, 120, 160, and 200 μg of total protein from HEK293 cells
lysate and measured PDH enzyme activity according to the manufacturer protocol
(#ab109882). Briefly, using a 96-well plate, 50 μl of blocking solution was added into each
well, followed by addition of 50 μl of samples into the each well. The solutions were mixed,
and a dipstick was placed in each well. After 60 minutes, when the entire content of each
well was wicked up onto the dipsticks, 40 μl of sample buffer was added and allowed to
wick up entirely (~15 minutes). After removing the wicking pads from each dipstick, they
were transferred to new wells containing 300 μl of activity buffer and incubated for 60
minutes. Then, dipsticks were washed in Millipore water for 5 minutes in new wells and
allowed to dry. Digital photographs of the dipsticks were taken using a ChemiDoc Imaging
System and the intensity of the bands was measured using ImageJ and generated PDH
standard curve (Figure 5b).

Sigma colorimetric PDH assay and NADH standard
The Sigma colorimetric PDH assay kit uses a different strategy and is a quantitative
assay. It uses NADH standards for each set of experiments. For the PDH standard curve, I
used different protein amounts of HEK293 cells (10, 50, 100 and 200 μg protein) lysed in
PDH lysis buffer. To generate NADH standards, 0, 2, 4, 6, 8, and 10 μL of the 1.25 mM
NADH standard solution was added into a 96 well plate which generates 0 (blank), 2.5, 5,
31

7.5, 10, and 12.5 nmole/well standards. Then, PDH assay buffer was added to each well to
bring the volume to 50 μL. The 96-well plate containing NADH standards and samples
were read at 450 nm using spectrophotometer.

Cell culture, transfection and harvesting
HEK293T cells were obtained from ATCC and maintained in Dulbecco’s modified
Eagle’s medium (DMEM, Gibco #11995065) containing 10% fetal bovine serum (FBS,
Gibco #26140079) and 1% Penicillin-Streptomycin (Pen/Strep, Gibco #15070063), at
37°C, and 5% CO2. Cells were transiently transfected with plasmids (pcDNA3, Nipsnap1,
APP-C31 as C-terminal region of APP) using SuperFect transfection reagent (QIAGEN
#301305) according to the manufacturer’s protocol and as described below. The day before
transfection approximately 7 ∗ 105 HEK293 cells were seeded per 60 mm dishes and
growth medium (DMEM+ 10% FBS+ 1% Pen/Strep) was added. Cells were incubated
overnight in 37°C and 5% CO2 incubator. On the day of transfection (cell confluency ~ 4060%), 5 μg DNA was diluted in DMEM (containing no FBS or antibiotics) to a final
volume of 100 μl. At this step serum and antibiotics will interfere with transfection
complex formation. Here 30 μl of SuperFect transfection reagent (Qiagen #301305) was
added to the DNA solution tube and was mixed a few times with pipetting. Samples were
incubated 10 minutes at room temperature (~24°C) to allow transfection complex
formation. During this time, growth medium was removed from petri dishes containing
HEK293 cells and was washed with 3 ml PBS. Then 1000 μl of growth medium (DMEM+
10% FBS+ 1% Pen/Strep) was added to the reaction tubes and was mixed twice and
immediately was transferred to the cells. At this step, serum and antibiotics will not
32

interfere, instead it will significantly enhance the transfection efficiency. These cells were
incubated for 2–3 h in 37°C and 5% CO2 incubator. Then medium containing transfection
complexes was removed from petri dishes. The cells were washed with 3 ml PBS. Fresh
growth medium was added to cells and were incubated for 48 h. Approximately 48h posttransfection, cells were harvested in PDH lysis buffer obtained from Abcam dipstick PDH
assay kit and PDH enzyme activity was performed as described previously.

Animal handling and tissue collection
All mice carrying Nipsnap1 -/- alleles (KD), and wild type (WT) were maintained
in the University of Memphis or Beaumont Research Institute animal facilities according
to guidelines stipulated by the National Research Council. All experimental procedures
were done following an approved protocol by the Beaumont Research Institute animal
facility (Protocol AL-19-06), University of Memphis Institutional Animal Care and Use
Committee (Protocol #0784). For tissue collection special care was taken to handle and
treat all animals the same, to minimize variability within and between experimental groups.
The mice were euthanized by cervical dislocation before dissection and tissue collection.
Immediately after euthanasia, brain tissue was removed and placed in a 1.5 ml micro
centrifuge tube and frozen in liquid nitrogen. Both WT and KD brain samples were
collected in the same manner and were stored at -80 °C until use. All brain samples were
collected from 13 months old female animals.
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Measuring PDH protein level in Nipsnap1 deficient mice
To further investigate Nipsnap1-PDH complex interaction, I measured PDH levels
in Nipsnap1 deficient mice brains. Three 13-month-old Nipsnap1 KD female mice and
three age-matched female controls were selected and kept in separated cages. Since PDH
activity changes during energy deprivation (Gudiksen and Pilegaard 2017), to stabilize
metabolism in each animal, food was removed from cages 16 hours before brain and liver
tissue collection. Brains were homogenized in Triton X100 Lysis Buffer (TX-LB) (50 mM
Tris-Cl PH 7.4, 200 mM NaCl, 1% Triton X100, 2.5 mM MgCl2, 5% Glycerol, 1 mM
Sodium Orthovanadate, 25 mM NaF and 5% Protease inhibitors Cocktail) using dounce
homogenizer. PDH, Nipsnap1 and β-actin protein levels were measured using immune
blotting (anti-PDH antibody, Abcam #ab168379, anti-Nipsnap1 antibody, Cell Signaling
#13226 and anti-β-actin antibody, Abcam # ab8227).
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Figure 4 Experimental strategy that was used to measure PDH protein level and
enzyme activity in mouse brain tissue. Aged matched Nipsnap1 WT and KD mice
were fasted for 16 hours. Then brain tissues were obtained and PDH protein level and
enzyme activity were measured using immunoblotting and PDH enzyme assay kit.

Measuring PDH enzyme activity in Nipsnap1 deficient mice brain using Sigma kit
To study the effects of Nipsnap1 on PDH enzyme activity, eight age-matched
animals (four KD and four WT) were fasted for 16 hours before tissue collection (Figure
4). Using glass tissue grinder, the brain tissues were homogenized in ice-cold PDH assay
buffer (100 mL buffer per 10 mg tissue) from PDH activity assay kit (Sigma MAK183).
Tubes were kept on ice for 10 minutes followed by centrifuging at 10,000*g for 5 minute
to remove insoluble material. Then, the supernatants were transferred to a fresh tube and
10 μL of samples were added to duplicate wells and PDH assay buffer was added to a final
volume of 50 μl.
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Table 2 Reaction mixes for the Sigma PDH assay kit.
Reagent

Standards and samples

Sample blank

PDH assay buffer

46 μl

48 μl

PDH developer

2 μl

2 μl

PDH substrate

2 μl

-

In the next step, 50 μl of reaction mix was added to each well according to the Table
2 and incubated the plate at 37 °C for 2-3 minutes. Then, the initial measurement was taken
using a spectrophotometer at 450 nm. The measurements were continued taken every 5
minutes until the value of the most active sample was greater than the value of the highest
standard which was 12.5 nano molar. Finally, the PDH enzyme activity was calculated
according to the following formulas as were mentioned in manufacturer protocol (Sigma
MAK183).

𝑃𝐷𝐻 𝑒𝑛𝑧𝑦𝑚𝑒 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
•

𝑆𝑎
(𝑅𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒)𝑥 𝑆𝑣

Sa= Amount of NADH (nmole) generated in unknown sample well between
Tinitial and Tfinal from standard curve.

•

Reaction Time = Tfinal – Tinitial (minutes)

•

Sv = sample volume (ml) added to well
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Measuring PDH enzyme activity in Nipsnap1 deficient mice liver
To measure changes in PDH protein levels in the livers of Nipsnap1 deficient mice
versus control, livers were homogenized in ice-cold PDH assay buffer (10 mg tissue in 100
μL buffer) from PDH activity assay kit (Sigma MAK183). Since liver tissue contains small
molecules that may interfere with PDH assay, I used the ammonium sulfate precipitation
method to selectively extract proteins. For each sample, 100 ml of lysate was added to a
tube and 200 ml of saturated ammonium sulfate (~4.1M at room temperature, bioPLUS™
#40120153) and kept on ice for 20 minutes. In the next step, the tubes were centrifuged at
10,000*g for 5 minutes and the supernatant was discarded. The pellet was resuspended to
200 ml with PDH assay buffer. Afterwards, PDH assay was performed as described before.

Statistical Analysis.
For PDH experiments, a paired two-tailed T test was used to evaluate the
significance of the change in three independent experiments. Intensity of dipstick PDH
assay bands were quantified using ImageJ software.
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3. Results
Abcam dipstick PDH standard curves
To generate a standard curve for the Abcam dipstick PDH enzyme activity assay
kit (#ab109882), different protein amounts from HEK293T cell lysates were used (Figure
5a). The dipstick bands were digitized, and the intensity of the bands were quantified using
ImageJ software. As shown by Figure 5b, the assay did not appear to be linear, and the
dynamic range of the assay was narrow (between 40-100 μg of total protein).

a

b

Figure 5 Abcam dipstick PDH enzyme activity standard curve. a) Different amounts
(40μg to 200μg) of total protein from untransfected HEK293cell lysates were loaded on
to the Abcam dipsticks and processed per manufacturer’s protocol. b) The resulting
bands were quantified using ImageJ software.
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PDH enzyme activity in HEK293 cells using Abcam dipstick assay
Based on the PDH standard curve result (Figure 5), 70 μg of protein lysate was used
for the first set of experiments to test if transient transfection of Nipsnap1 or APP-C31
affected endogenous PDH activity. APP-C31 was used to test the hypothesis that APP C31
could directly or indirectly through binding to endogenous Nipsnap1 affect PDH enzyme
activity in HEK293 cells. The cells were transfected with Nipsnap1-HA, APP-C31 or
pcDNA3 vector as control. Two days after transfection, the cells were lysed in PDH assay
buffer, protein amount was determined by BCA method. A total of 70μg of protein lysate
was incubated with the Abcam dipstick PDH assay according to manufacturer’s protocol.
Transient transfection with Nipsnap1 or APP-C31 did not produce a significant change in
PDH activity (Figure 6).
These results may be interpreted in two ways: 1) There was no significant decrease
in PDH enzyme activity after transfection of Nipsnap1 or APP-C31, or 2) An increase in
PDH activity may be not have been observed due to saturation effect on the assay system.
To address the potential saturation effect, we used lower amount of protein for the
following experiments.
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Figure 6 PDH enzyme activity using Abcam dipsticks with 70 μg protein. HEK293
cell lysates transfected with pcDNA3, Nipsnap1, or APP-C31 were used to perform PDH
enzyme activity assays in three independent experiments. There was no significant PDH
enzyme activity changes in HEK293 transfected with Nipsnap1 and APP-C31 compared
with pcDNA3 as control. (Means ± SEM, paired two-tailed T test and n=3, P value >
0.05.

To address the issue of possible saturation, a lower amount of protein lysate (45 ug)
was used in the second set of experiments. Similar to above experiment, HEK293 cells
were transfected with pcDNA3, Nipsnap1-HA, and APP-C31 and PDH enzyme activity
was measured 2 days after transfection. Nipsnap1 transfection produced a modest but not
significant increase in PDH activity. In contrast, APP-C31 transfection produced a
significant (p < 0.05, paired two-tailed student’s t-test) increase in PDH activity (Figure 7).
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*

Figure 7 PDH enzyme activity using dipsticks with 45 μg protein. HEK293 cell
lysates transfected with pcDNA3, Nipsnap1-HA, or APP-C31 were used to perform
PDH enzyme activity assays in three independent experiments. PDH enzyme activity
significantly (p < 0.05, paired two-tailed student’s t-test) increased in HEK293 cells
transfected with APP-C31 compared with pcDNA3 as control. However, there was no
significant change in PDH enzyme activity in HEK293 cells transfected with Nipsnap1HA compared with pcDNA3 as control. Means ± SEM, paired two-tailed T test and n=3.

PDH and NADH standard curves using enzyme-coupled colorimetric assay
Since the Abcam dipstick PDH enzyme assay had a narrow dynamic range, I
investigated whether a different approach would be more quantitative. The Sigma PDH
enzyme assay is an enzyme coupled colorimetric assay (Sigma, Inc) that can be quantified
in solution using a spectrophotometer as described previously. Different amounts of
NADH substrate and HEK293 cell lysates were used and the PDH enzyme activity was
measured using spectrophotometer to measure NADH and PDH standard curve.
First, assay linearity and dynamic range was examined by generating a standard
curve using specified amounts of purified NAD (Figure 8a). The result shows that the
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Sigma colorimetric PDH assay is working well, and the NAD standards curve is linear.
Then a PDH protein standard curve was produced using different amounts of HEK293 cell
lysates (Figure 8b). The PDH protein standard curve was also linear, suggesting that this
assay may be more reliable.
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a

b

Figure 8 Sigma colorimetric NAD and PDH assay standard curves. This PDH
enzyme assay is a coupled enzyme reaction, which measures PDH enzyme activity
using spectrophotometer at 450 nm. a) NADH standard curve using 0, 2.5, 5, 7.5,
10, and 12.5 nmole of NAD. b) PDH standard curve using different protein amount
of HEK293 cells (10, 50, 100 and 200 μg protein).
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PDH enzyme activity in HEK293 cells
Based on the results from PDH standard curve (Figure 8b), 150 μg cell lysate was
selected for the next set of experiments to determine if transient transfection of Nipsnap1
and APP-C31 affects PDH enzyme activity in HEK293 cells. The PDH enzyme activity
assay was performed as described previously. Consistent with the previous experiments,
Nipsnap1 transfection did not significantly affect PDH activity (Figure 9). However, in
contrast with previous experiments, APP-C31 also did not significantly change PDH
activity. Taken together, the results in previous section, where we used dipstick PDH assay,
and the results in this section, using a different assay, did not produce consistent results.
These results suggest that using HEK293 and transient transfection approach may not
produce reliable results. Therefore, in the following experiments, I focused on
characterizing PDH levels and enzyme activity using mouse Nipsnap1 knock-down tissues.

.
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Figure 9 PDH Enzyme activity in HEK293 cells using Sigma kit. HEK293 cell
lysates transiently transfected with pcDNA3, Nipsnap1-HA, and APP-C31 were used to
perform PDH enzyme activity assay. PDH enzyme activity was measured using
spectrophotometer at 450 nm. There was no significant PDH enzyme activity changes in
HEK293 transfected with Nipsnap1-HA and APP-C31 when it was compared to
pcDNA3 as control. (Means ± SEM, paired two-tailed T test and n=3, P value > 0.05,).

Nipsnap1 deficiency does not alter PDH protein level in brain
To investigate the effect of Nipsnap1 deficiency on PDH, I measured PDH protein
level in the brain lysate of Nipsnap1 KD mice using immunoblotting. Three 13-month-old
Nipsnap1 KD female mice and three age-matched female Nipsnap1 WT as control were
selected and kept in separate cages. To provide a stable energy supply and avoid PDH
activity changes, food was removed from each cages 16 hours prior brain tissue collection
(Gudiksen and Pilegaard 2017). Brains were homogenized in TX-LB. Then, PDH,
Nipsnap1 and, β-actin protein levels were measured using immunoblotting.
As shown by Figure 10, Nipsnap1 protein was completely absent in the brain of
Nipsnap1 KD mice. Moreover, we found that PDH protein levels were not changed in the
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brain of Nipsnap1 deficient mice (Figure 10). This result was not a surprise due to the fact
that PDH complex is an important enzyme in providing energy for cells and PDH
deficiency leads to cerebral developmental abnormalities. However, our Nipsnap1 KD
mice do not show any abnormalities in their phenotype.

Figure 10 The effect of Nipsnap1 deficiency on PDH protein level. Three Nipsnap1
KD mice and three age-matched WT mice were fasted for 16 hours before tissue
collection. Brains were homogenized in TX-LB. PDH, Nipsnap1 and actin protein levels
were measured using immunoblotting (Means ± SEM, paired two-tailed T test, P value
> 0.05, n=3, KD: Knockdown and WT: Wild type as control,).

Nipsnap1 deficiency does not change PDH enzyme activity in the brain
To study the effects of Nipsnap1 on PDH enzyme activity, Sigma colorimetric PDH
assay was used due to assay linearity, dynamic range, and spectrophotometry measurement
method, which provides a more reliable measurement of PDH activity. Eight age-matched
animals (four KD and four WT) were fasted for 16 hours before tissue collection same as
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in previous experiments to avoid PDH enzyme activity changes (Gudiksen and Pilegaard
2017). Brains were lysed in PDH assay buffer and PDH enzyme activity was measure using
spectrophotometer. As displayed in Figure 11, there was a slight, but statistically
insignificant, decrease in PDH enzyme activity in the brain of Nipsnap1 KD mice
compared with control group.
The reason that we did not see any significant changes could be due the fact that
Nipsnap1 is exclusively expressed in neurons; however, PDH is expressed in both neurons
and glial cells in the brain.
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Figure 11 PDH enzyme activity in mouse brain. The effect of Nipsnap1 deficiency on
PDH enzyme activity in mice brain. Nipsnap1 KD (n=4) and WT (n=4) mice (13-monthold) were fasted for 16 hours before tissue collection. Brains were homogenized in PDH
lysis buffer, and PDH enzyme activity assay was performed according to manufacturer’s
protocol (Sigma MAK183). There was no significant difference in PDH enzyme activity
in Nipsnap1 deficient mice compared to WT mice. (Means ± SEM, paired two-tailed T
test, P value: 0.3270, KD: Knockdown, WT: Wild type as control).

Nipsnap1 deficiency moderately decreased PDH enzyme activity in the liver
Brain is a heterogenous tissue that consists of different types of cells such as
neurons and glial cells. While PDH is expressed in neuronal and glial cells, Nipsnap1 is
expressed only in neurons. For this reason, I used liver tissue that highly expresses both
Nipsnap1 and PDH proteins. Aged-matched Nipsnap1 KD (n=8) and eight WT (n=8) mice
were fasted for 16 hours before liver tissue collection to avoid PDH activity changes due
to food intake. Livers were lysed in PDH assay buffer followed by performing the
ammonium sulfate precipitation method to remove small interfering molecules in liver,
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which may intervene in measuring PDH enzyme activity. Then, PDH enzyme activity was
measured using spectrophotometer. As displayed in Figure 12, PDH enzyme activity was
moderately decreased in the liver of Nipsnap1 KD mice compared to control; however, this
decrease was not significant. It is possible that this change would become significant if the
sample size was increased.

Figure 12 The effect of Nipsnap1 deficiency on PDH enzyme activity in mouse liver.
Aged matched 13-month-old Nipsnap1 KD (n = 8) and WT (n = 8) mice were fasted for
16 hours before tissue collection. Liver tissues were homogenized in PDH lysis buffer
followed by measuring PDH enzyme activity according to the manufacturer’s protocol
(Sigma MAK183). There was a moderate decrease in PDH enzyme activity in the liver
of Nipsnap1 deficient mice compared to control (Means ± SEM, paired two-tailed T test,
P value: 0.088, KD: Knockdown, WT: Wild type as control,).
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4. Discussion
The major focus of this chapter was to optimize conditions to measure PDH enzyme
activity and study the effect of Nipsnap1 deficiency on PDH enzyme activity. I used two
different PDH enzyme assay kits; 1) Abcam dipstick PDH enzyme activity assay kit
(#ab109882) and 2) Sigma colorimetric PDH activity assay kit (#MAK183). The Abcam
dipstick PDH standard curve was not linear and hit the saturation very quickly at total
protein amount of ~200 μg, which suggest that this kit may not very reliable. In addition,
using 45 μg of protein lysate from HEK293 cells overexpressing APP-C31 caused
significant increases in PDH enzyme activity, higher amounts of protein lysate (70 μg) did
not change PDH enzyme activity. Overexpression of Nipsnap1 did not have any effect on
PDH enzyme activity). To verify these results, I used the Sigma PDH assay kit which uses
a different strategy and has a linear NADH and PDH standard curve. Overall,
overexpression of Nipsnap1 did not appear to have any effect on PDH enzyme activity in
HEK293 cells. These results may be due to different factors. The main reason might be
that there is endogenous expression of Nipsnap1 in HEK293 cells. Therefore, to best
address the role of Nipsnap1 might be to knock-down Nipsnap1 with siRNA for future
experiments. However, there is an issue of compensation by Nipsnap2. Therefore, both
Nipsnap1 and Nipsnap2 gene expression may need to be knocked out for future
experiments. This may be complicated, because it is possible that double deletion of
Nipsnap1 and Nipsnap2 may be lethal.
PDH is necessary for providing required energy for cells and PDH deficiency leads
to neurological dysfunctions (Pliss et al. 2013). In addition, while PDH is expressed in
neurons and glial cells in brain, Nipsnap1 is only expressed in neurons and not in glial
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cells. Since Nipsnap1 deficient mice do not show developmental abnormalities, I was not
expecting to observe a significant difference between PDH protein levels in Nipsnap1 KD
mice and control which was confirmed by the experiments. In addition, there were no
noticeable changes in PDH enzyme activity in Nipsnap1 KD mice compared with control
group. Brain is a heterogenous tissue consisting of glial and neuronal cells. While Nipsnap1
is exclusively expressed in neurons, PDH expression occurs in both glial cells and neurons.
For this reason, we were unlikely to see a significant change in PDH enzyme activity in
the brain of Nipsnap1 deficient mice. Importantly, this result is consistent with the
observations that brain tightly regulates the activity of PDH complex during prolonged
fasting or a high fat diet due to constant need of brain cells for glucose through oxidative
phosphorylation to generate ATP (Amaral 2013; Gray, Tompkins, and Taylor 2014; Harris
et al. 2002).
Since both Nipsnap1 and PDH are highly expressed in liver, I was expecting to see
significant changes in PDH enzyme activity in Nipsnap1 KD liver. However, there was
only a moderate (not significant) decrease in PDH activity in Nipsnap1 deficient liver.
Nipsnap1 and Nipsnap2 have high sequence similarity with mitochondrial targeting
sequence at the N-terminus, suggesting the possibility of similar functions. Recently, one
group has shown that Nipsnap1 and Nipsnap2 have redundant functions in PARKINdependent mitophagy (Princely Abudu et al. 2019). Since Nipsnap1 gene has been deleted
from the germline in our mouse model, it is possible that lack of Nipsnap1 expression has
been compensated physiologically by Nipsnap2. A good strategy for future experiments
might be the use of Nipsnap1 KD with siRNA in cells in addition to Nipsnap2 KD to avoid
the compensation effect. In addition, we found that Nipsnap1 deficiency does not have a
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significant effect on PDH enzyme activity in the liver and brain of Nipsnap1 KD mice. It
is possible that lack of Nipsnap1 has been compensated physiologically by Nipsnap2 in
our mice model. Overall, it does not appear that PDH interaction with Nipsnap1 has a
functional consequence on PDH protein level or its enzyme activity but may just serve to
localize Nipsnap1 to PDH as a sensor.
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Chapter III: Direct binding of NAD(P)H and ATP to the highly conserved Cterminal domain of Nipsnap1

1. Introduction
As mentioned in Chapter 1, the C-terminal region of Nipsnap1 contains a domain
(named Nipsnap domain) that is highly conserved throughout evolution. There is limited
knowledge about the 3-dimensional structure of the conserved Nipsnap protein domain. A
mammalian Nipsnap crystal structure is not available to date. The only known structure,
closest to Nipsnap protein family, relates to a hypothetical protein in Agrobacterium
tumefaciens A biological assembly image is available for hypothetical protein atu4242
(1VQS)

(https://www.rcsb.org/structure/1vqs)

and

atu5224

(1VQY)

(https://www.rcsb.org/structure/1VQY) from Agrobacterium tumefaciens at the level of
1.50 A° and 2.40 A° resolution, respectively. Another crystal structure is available for
atu4242 (2AP6) (https://www.rcsb.org/structure/2AP6) at 2.5 A° resolution. The function
of this conserved domain is not yet understood.
To gain insights into the molecular function of the conserved domain of Nipsnap1
protein, we used a protein modeling approach to screen for potential ligands (Yarbro et al.
2018). The C-terminal Nipsnap1 domain was modeled using experimental crystal
structures 1VQS and 1VQY. Using the model of the Nipsnap1 C-terminal region, a
database of 74,378 molecules from DrugBank and ChEMBL databases were screened with
FINDSITEcomb (Zhou and Skolnick 2013). NADH and NADPH were the top 2 ranked
ligands for Nipsnap1, 1VQS and 1VQY (Yarbro et al. 2018). Preliminary data from our
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group confirmed the interaction between Nipsnap1 with NADH and NADPH using
Circular Dichroism Spectrophotometry (Yarbro et al. 2018).
In this chapter, I aimed to 1) verify the predicted interaction between Nipsnap1 with
NADH and NADPH using biochemical binding assays using mouse brain lysates. 2)
Investigate if these interactions are direct by using purified Nipsnap1 protein in pull-down
assays. 3) Verify that the C-terminal region of Nipsnap1 is involved in the interaction with
NADH and NADPH. 4) Map the amino acid residues in Nipsnap1 that play an important
role in NADH binding using a site-directed mutation approach.

54

2. Methods
HEK293 cell transfection and cell lysate preparation
HEK293 cells were grown, maintained, and transfected with Nipsnap1 mutant
constructs, pcDNA3 or wild-type Nipsnap1-HA as described previously. To lyse the
transiently transfected HEK293 cells, 60 mm dishes were placed on ice, media was
discarded, and cells were washed with 3 ml ice-cold PBS. Cells were lysed in 0.5 ml TXLB buffer. Afterwards, cells were scraped from the plates and lysates were transferred to
microcentrifuge tubes on ice. Samples were cleared by centrifugation at 14,000 rpm at 4°
C for 30 min. Lysates were transferred to a new tube on ice for pull-down assay.

Brain lysate preparation, pull-down, and immunoblotting assays
To study Nipsnap1 interaction with NAD, NADP, ATP, AMP and GTP, six 13-months
age-matched animals (three KD and three WT) were used (Figure 13). Using glass tissue
grinder, the brain tissues were homogenized in ice-cold TX-LB (50 mM Tris-Cl PH 7.4,
200 mM NaCl, 1% Triton X-100, 2.5 mM MgCl2, 5% Glycerol, 1 mM
sodium orthovanadate, 25 mM NaF and 5% protease inhibitors cocktail) using a dounce
homogenizer (100 μL buffer per 10 mg tissue). Samples were cleared by centrifugation at
14,000 rpm at 4° C for 30 min. Pull down and immunoblotting assays were performed as
following.
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Figure 13 Experimental design to identify specificity of NAD interaction with Nipsnap1. Pull-down assay was performed
on Nipsnap1 KD and WT mice brain lysates using NAD-Separopore, NADP-Separopore, AMP-Separopore, ATP-Separopore,
GTP-Separopore, and Separopore followed by immunoblotting.

56

Nipsnap1 KD and WT brain lysates (1mg protein), or 400 µl of HEK293 cells lysates
(400 µg protein) were transferred to a new microcentrifuge tube on ice. TX-LB was added
to the lysates to bring up the volume to 500 µl. Using wide-bore pipet tips, 50 µl of
Separopore beads (Table 3) were added to each sample tube and incubated 1 h at 4°C on
rotator. Tubes were spun at 500* g, at 4°C for 1 min. Then solution was removed sing a
27Ga needle. Tubes containing Separopore beads were washed 3 times in 500 µl ice-cold
TBST buffer (1X Tris-buffered saline + 0.1% Tween 20). For the last wash samples were
transferred to new tubes to reduce non-specific binding of beads.
Then, beads were resuspended in 25µl 2X SDS sample buffer. Samples were loaded on
10 % SDS-PAGE and transferred to nitrocellulose membrane. Membrane was blocked in
5% non-fat dry milk in TBST followed by incubation in primary antibody (1:1000 for 2h),
3 times washes, secondary antibody (1:5000 for 2h), and 5 times washes. Pierce ECL
Western blotting substrate (Thermo Scientific #32106) was used, and membrane was
exposed to film (UltraCruz # sc-201696) for various times (3 sec to 5 minutes, depending
on signal strength) in the dark room. The film was visualized using Carestream GBX
developer (#3014366) and fixer (#3014368) in the dark room.
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Table 3 list of reagents for pull-down assays
Reagents

Company

Catalog number

NAD-Separopore 4B-CL

Bioworld

#20181024

NADP-Separopore 4B-CL

Bioworld

#20181023

AMP-Separopore 4B-CL

Bioworld

#20181079

ATP-Separopore 4B-CL

Bioworld

#20181080

GTP-Separopore 4B-CL

Bioworld

#20181066

Separopore 4B-CL

Bioworld

#20181032

Nipsnap1 (D1Y6S) Rabbit Ab

Cell Signaling Technology

#13226S

Anti-Nipsnap1 Ab

Abcam

#ab67324

Anti-HA tag antibody

Abcam

# ab9110

Goat Anti-Rabbit IgG (HRP)

Abcam

#ab205718

ATP disodium salt hydrate

Sigma

A2383

ADP sodium salt

Sigma

A2754
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Bacterial expression and purification of Nipsnap1
The design of bacterial expression constructs and purification of Nipsnap1 fulllength and C-terminal domain was performed by Samantha Gagasan and described
previously (Yarbro 2018). Briefly, the mammalian Nipsnap1 gene, minus the
mitochondrial signal sequence, was engineered to use Escherichia coli -optimized codons
for maximal expression. The Nipsnap1 full-length and C-terminal cDNA were subcloned
into pET-28a plasmids containing N-terminal (His)6-tag. These plasmids were used to
transform E. coli BL21 (DE3) cells. Afterwards, the His-tagged Nipsnap1 FL and CT
proteins was purified using Ni-Affinity chromatography.

Site-directed mutagenesis
To map the residues of Nipsnap1 that are involved in NAD and ATP interaction, I
used two different strategies. First, we used the protein sequence alignment to identify
highly conserved amino acids. Then we used a tool called NADBinder by Ansary &
Raghava to identify preferred NADH binding residues (Ansari and Raghava 2010).
Mutations on a selected set of amino acids were made using the QuikChange II SiteDirected Mutagenesis Kit (Agilent #200523). This kit provides site-specific mutation in
double-stranded plasmids within three steps (>80% efficiency). The procedures are
described as below.
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Designing mutagenic oligonucleotide primers
The mutagenic oligonucleotide primers were designed to replace conserved amino
acids in the C-terminal region of Nipsnap1 with non-preferred NAD-interacting residues
such as Ala, Glu, Leu, and Lys according to Ansari & Raghava (Ansari and Raghava 2010).
Lengths of primers were designated between 25 and 45 bases with the melting temperature
(Tm) ≥78°C. The desired mutation was placed in the middle of the primer with ~10–15
bases of correct sequence on either side. Primers were designed using the QuikChange
primer

design

online

https://www.agilent.com/store/primerDesignProgram.jsp?_requestid=119614

tool
(Table 4

and Figure 14) by entering mouse Nipsnap1 consensus CDS nucleotide sequence
(Nipsnap1_NM_008698).
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Figure14 Designing E199A/W200A mutagenic primer using QuikChange Primer
Design Program. Residues 199 and 200 located in Nipsnap1 were replaced with Ala.
https://www.agilent.com/store/primerDesignProgram.jsp?_requestid=119614
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Table 4 List of oligonucleotide primers used in this study to make site-directed mutation.
Name

Sequence

Y190A/K191A -F

5´-ATCATGGTTCCTGGCTTGAGTGCAGCTGTCCTCAGCTCATAGATATTGGGG-3´

Y190A/K191A -R

5´-CCCCAATATCTATGAGCTGAGGACAGCTGCACTCAAGCCAGGAACCATGAT-3´

E199A&W200A-F

5´- AAGCCAGGAACCATGATTGCAGCGGGAAACAACTGGGCTCG-3´

E199A&W200A-R 5´- CGAGCCCAGTTGTTTCCCGCTGCAATCATGGTTCCTGGCTT-3´
G219K/F221V-F

5´-GAGAACCAGGAGGCGGTGAAAGGCGTCTTTTCACAAATAGGAG-3´

G219K/F221V-R

5´-CTCCTATTTGTGAAAAGACGCCTTTCACCGCCTCCTGGTTCTC-3´

I225K/G226K-F

5´-AGGCGGTGGGAGGCTTCTTTTCACAAAAAAAAGAGCTCTACGTGG -3´

I225K/G226K-R

5´- CCACGTAGAGCTCTTTTTTTTGTGAAAAGAAGCCTCCCACCGCCT-3´

H233L/W235L-F

5´-GCTCTACGTGGTACACCTCTTATTGGCCTACAAAGATTTGC-3´

H233L/W235L-R

5´-GCAAATCTTTGTAGGCCAATAAGAGGTGTACCACGTAGAGC-3´
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Mutant strand synthesis reaction
Mutagenic primers were synthesized by GENEWIZ (NJ, USA). pcDNA3–Nipsnap1–
HA (Tummala et al. 2010) was used as the template to make point mutations using
QuikChange II Site-Directed Mutagenesis Kit (Agilent #200523) according to the
manufacturer’s protocol. Control reaction was prepared as follows:
10× reaction buffer
pWhitescript 4.5-kb control plasmid (5 ng/μl)
Oligonucleotide control primer #1
Oligonucleotide control primer #2
dNTP mix
ddH2O
PfuUltra HF DNA polymerase (2.5 U/μl)

5 μl
2 μl (10 ng)
1.25 μl (125 ng)
1.25 μl (125 ng)
1 μl
38.5 μl
1 μl

Sample reactions were prepared as follows:
10× reaction buffer
pcDNA3_Nipsnap1-HA plasmid (5 ng/μl)
Oligonucleotide mutagenic primer #1
Oligonucleotide mutagenic primer #2
dNTP mix
ddH2O
PfuUltra HF DNA polymerase (2.5 U/μl)

5 μl
X μl (20 ng)
X μl (125 ng)
X μl (125 ng)
1 μl
Final volume of 50 μl
1 μl

Each reaction used the following cycling parameaters: 95°C for 30 seconds, 95°C for 30
seconds (12 cycles), 55°C for 1 minute, and 68°C for 8 minutes. Samples were placed on
ice for 2 minutes to cool. In the next step, 1 μl of the Dpn I restriction enzyme (10 U/μl)
was added to each tube and incubated at 37°C for 1 h to digest the parental DNA.
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Transformation of XL1-Blue supercompetent cells
XL1-Blue supercompetent cells were used to amplify the mutant constructs using
QuikChange II Site-Directed Mutagenesis Kit (Agilent #200523). The tube containing
XL1-Blue cells were thawed on ice. 50 μl of XL1-Blue cells were transformed in an icecold 14 ml BD plastic culture round-bottom tube (Fisherbrand # 14-956-6A). Treated DNA
with Dpn I (1 μl) were transferred to XL1-Blue supercompetent cells. The tubes were
gently swirled to mix the reactions. The reaction tubes were incubated on ice for 30
minutes. The transformation reactions tubes were heat pulsed for 45 seconds at 42°C and
then were place immediately on ice for 2 minutes. S.O.C. medium was preheated to 42°C.
Then, 0.5 ml was transferred to each transformation reactions. The tubes were incubated at
37°C for 1 hour with shaking at 250 rpm. Sample mutagenesis (250 μl) were spread on
agar plates containing ampicillin (Invitrogen #Q60120). For pWhitescript mutagenesis
control, 250 μl was plated on an agar plate containing ampicillin, 80 μg/ml X-gal and 20
mM IPTG. The plates were incubated at 37°C for more than 16 hours. Form each sample
mutagenesis plates, four colonies were selected and separately were grow in 5 ml growth
liquid medium containing ampicillin (Invitrogen #Q60020) in 14 ml BD plastic culture
round-bottom tube (Fisherbrand # 14-956-6A). The tubes were incubated at 37°C for 1216 hours with shaking at 250 rpm. All constructs were confirmed by Sanger DNA
sequencing, which was performed by GENEWIZ (NJ, USA).
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Restriction enzyme digestion
Plasmid DNA was purified using QIAprep Spin Miniprep Kit according to manufacturer’s
protocol (Qiagen # 27104). The Restriction enzyme digestion was set up as follows.

Plasmid DNA
10X NEBuffer 2.1 (BioLabs # B7202)
HindIII (BioLabs #R0104)
XhoI (BioLabs #R0146)
Nuclease-free Water

1 μg
5 μl (1X)
1.0 μl (20 units)
1.0 μl (20 units)
Total 50 μl

XhoI cut site C/TCGAG and HindIII cut site A/AGCTT.

The reaction tubes were incubated at 37 °C for 1 hour. Then, 10 μl of samples were mixed
with 2 μl DNA loading dye (6X) and loaded in 1% agarose gel.

Ligand Docking Simulations
The structure of the C-terminal region (110 amino acids) of Nipsnap1 was modeled
using

the

Phyre2

protein

modeling

web

server

(http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) (Kelley et al. 2015). The
initial ligand conformations for NADH, NAD+, ADP, and ATP were taken from Pubchem
(https://pubchem.ncbi.nlm.nih.gov/). Ligands and proteins were prepared (missing atoms
and polar hydrogens and charges were added) using AutoDockTools 1.5.7. A blind docking
approach was used with a grid large enough to contain the entire Nipsnap1 C-terminal
domain structure. Docking was performed using AutoDock Vina (Trott and Olson 2009),
with exhaustiveness set to 64. Ten docking conformation with the lowest energy were
saved and analyzed.
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Protein residues that commonly interacted with proteins were determined using the
following procedure: (1) residue-ligand distances for 10 lowest energy conformations were
determined from the shortest distance between any atom of the residue and any ligand
atom, (2) the average residue-ligand distance for each residue was calculated using a
Boltzmann weighted average across the 10 lowest energy conformations, and (3) residues
were ranked by this Boltzmann weighted average residue-ligand distance.

Statistical Analysis:
For pull-down experiments, a paired two-tailed T test was used to evaluate the
significance of the change in three independent experiments.
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3. Results
Nipsnap1 binds to NAD, NADP and ATP, but not to AMP and GTP
To test the prediction that Nipsnap1 C-terminal domain interacts with NADH and
NADPH, we performed biochemical pull-down assays using brain lysates from wild-type
and Nipsnap1 KD as control. Brain lysates were incubated with Separopore beads
covalently linked to NAD+ and NADP+. Since NAD/NADP include an adenosine
diphosphate (ADP) group, we also performed pull-down experiments using AMPSeparopore and ATP-Separopore beads. Lastly, as a negative control we used GTPSeparopore. As shown by Figure 13, we found that NAD and NADP bound to Nipsnap1
protein in mouse brain lysates. Interestingly, we also found that ATP binds to Nipsnap1
protein (Figure 15). In contrast, Nipsnap1 did not bind to AMP or GTP. These results
suggest that Nipsnap1 may preferentially bind to NAD, NADP and ATP (Figure15). In
addition, these results suggest that an Adenine covalently attached to two or more
phosphates may be required for Nipsnap1 binding.
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Figure 15 Nipsnap1 binds to NAD, NADP and ATP but not AMP and GTP. AntiNipsnap1 antibody (Cell Signaling) specifically detects Nipsnap1 protein (arrow) in
brain lysates (left panel). Pull-down assays were performed using WT brain lysates
incubated with NAD-Separopore, NADP-Separopore, AMP-Separopore, ATPSeparopore, GTP-Separopore, and Separopore (right panel). Nipsnap1 interacts with
NAD, NADP and ATP. (IB; Immunoblotting, PD; Pull-down, WT: wild type, KD;
knock-down, black arrow shows Nipsnap1 band).

Nipsnap1 directly binds to NAD, NADP and ATP
Since brain lysate consists of a variety of complexes and compounds, we
investigated whether the interaction between Nipsnap1 and NAD, NADP and ATP is direct
or indirect through other protein complexes that exist in brain. To address this, pull-down
assays were performed using purified bacterially expressed Nipsnap1 Full length (pNipsnap1 FL) protein (Table 5). Since the protein modeling and virtual ligand screening
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was performed using the C-terminal region of Nipsnap1, we also tested if Nipsnap1 Cterminal (p-Nipsnap1 CT) fragment (Table 6) directly binds to NAD and NADP.

Table 5 Purified Nipsnap1 Full length Sequence (-MTS) (261 aa), 30.79 KDa
GDLAAAGAVRFYSKDSEGSWFRSLFVHKVDPRKDAH
STLLSKKETSNLYKIQFHNVKPECLDAYNSLTEAVLPK
LHLDEDYPCSLVGNWNTWYGEQDQAVHLWRFSGGYP
ALMDCMNKLKNNKEYLEFRKERSKMLLSRRNQLLLE
FSFWNEPQPRAGPNIYELRTYKLKPGTMIEWGNNWAR
AIKYRQENQEAVGGFFSQIGELYVVHHLWAYKDLQSR
EETRNAAWRKRGWDENVYYTVPLVRHMESRIMIPLKI
SPLQ

Table 6 Purified Nipsnap1 C-Terminal Sequence (144 aa), 17.46 KDa
KLKNNKEYLEFRKERSKMLLSRRNQLLLEFSFWNEPQ
PRAGPNIYELRTYKLKPGTMIEWGNNWARAIKYRQEN
QEAVGGFFSQIGELYVVHHLWAYKDLQSREETRNAA
WRKRGWDENVYYTVPLVRHMESRIMIPLKISPLQ

p-Nipsnap1 FL and p-Nipsnap1 CT bands were verified by immunoblotting using
anti Nipsnap1 antibody (Figure 16a). Interestingly, the pull-down assay results showed that
NAD, NADP and ATP directly bind to p-Nipsnap1 FL (Figure 16b) as well as p-Nipsnap1
CT which is highly conserved (Figure 16c). These data suggest that Nipsnap1 can have a
binding pocket in its C-terminal for NAD, NADP and ATP.
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a

b

c

Figure 16 Purified Nipsnap1 FL and CT proteins directly bind to NAD, NADP, and ATP. a) Both purified fulllength and C-terminal region of Nipsnap1 (p-Nipsnap1 FL and p-Nipsnap1 CT) proteins were verified by
immunoblotting with anti Nipsnap1 antibodies (Cell Signaling and Abcam). b) Pull-down assays were performed using
Separopore linked NAD, NADP, AMP, ATP and GTP incubated with 100 μM purified p-Nipsnap1 FL (b) and pNipsnap1 CT (c) (IB; Immunoblotting, PD; Pull down, WT: wild type, KD; knock-down, n=3, black arrows show
Nipsnap1 full length bands, black-hollow arrows show Nipsnap1 C-terminal bands).

70

Nipsnap1 directly binds to NAD, NADP and ATP in a concentration dependent
manner.
We showed that 100 μM p-Nipsnap1 FL directly binds to NAD, NADP and ATP
with strong intensity (Figure 16b). To examine the relative affinities of NAD, NADP and
ATP to Nipsnap1, we performed pull-down assays using different concentrations of pNipsnap1 FL (1, 10, and 100 μM). Bound Nipsnap1 protein was detected by
immunoblotting (Figure 17). These experiments were repeated three independent times and
the band intensities were quantified. We found that at higher concentration (100μM),
Nipsnap1 bound equally well to all three ligands. However, 10 μM p-Nipsnap1 FL bound
stronger to NAD and NADP, and to a lesser extent to ATP. These results suggest that
Nipsnap1 may have a higher affinity to NAD than to ATP.Nipsnap
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Figure 17 p-Nipsnap1 FL protein directly binds to NAD, NADP and ATP in a
concentration dependent manner. Three different concentrations (1μM, 10μM, and
100μM) of p-Nipsnap1 FL were incubated with Separopore linked NAD, NADP and ATP
beads. Bound Nipsnap1 protein was detected by immunoblotting and the intensity of the
bands were quantified using ImageJ. NAD, NADP and ATP bind equally well at higher
concentrations of p-Nipsnap1 FL. (Means ± SEM and n=3 PD; Pull-down, WT: wild type,
KD; knock-down, black arrow shows Nipsnap1 band).
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NAD binding to Nipsnap1 is enhanced by higher concentration of ATP
The previous results suggest that ATP may regulate NAD and NADP binding to
Nipsnap1, either through competing with the binding pocket or through an allosteric
binding site. To investigate if ATP presence can modulate Nipsnap1-NAD interaction,
NAD pull-down assays were performed using p-Nipsnap1 FL protein in the presence of
various concentrations of ATP. As a control, pull-down assays were performed using the
same concentrations of ADP (Figure 18). Three independent experiments were performed,
and the results were quantified for statistical analysis. While lower concentrations of ATP
(10 μM and 100 μM) moderately decreased Nipsnap1-NAD interaction, higher
concentration of ATP (1000 μM) significantly (p < 0.05, paired student’s t-test) increased
this interaction. In contrast, ADP did not have any effect on Nipsnap1-NAD interaction
(Figure 18). These results suggest that at high concentrations, ATP may enhance Nipsnap1NAD interaction. One possibility is that ATP may allosterically enhance NAD binding to
Nipsnap1 through a distinct binding site. The other possibility is that ATP may change the
ionic strength of the Nipsnap1 binding pocket.
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Figure 18 NAD pull down using 100 μM p-Nipsnap FL protein in presence of ATP
and ADP. Three different concentrations (10μM, 100μM, and 1000μM) of ATP and
ADP were incubated with 100 μM of p-Nipsnap1 FL and Separopore linked NAD,
NADP and ATP beads. Bound Nipsnap1 protein was detected by immunoblotting and
the intensity of the bands were quantified using ImageJ. High concentration of ATP
(1000 μM) significantly increases Nipsnap1-NAD interaction. However, presence of
ADP does not appear to have an effect in Nipsnap1-NAD. (Means ± SEM, paired twotailed T test, n=3, IB; Immunoblotting, PD; Pull-down, WT: wild type, KD; knockdown, black arrow shows Nipsnap1 band).
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Mapping residues involved in Nipsnap1-NAD interaction
As indicated by Figure 16c, NAD, NADP and ATP directly bind to the C-terminal
region of Nipsnap1. To map what residues of Nipsnap1 are involved in ligand binding, we
performed mutation analysis. Residues within the C-terminal region of Nipsnap1 were
selected based on sequence conservation (Figure 19) and a potential nicotinamide binding
motif (Y-X10-Y), which is called scorpion domain because of its shape (Lee et al. 2010).
In addition, we used a tool called NADBinder website that predicts NAD-interacting
residues (http://www.imtech.res.in/raghava/nadbinder) based on primary amino acid
sequence (Ansari and Raghava 2010). Based on potential scorpion domain Y190 and W200
residues were selected. In addition, NADBinder predicted interactions with E199, W200,
G219, F221, F222, S223, Q224, I225, W235, A236, and Y237. According to the potential
scorpion like domain, NADBinder prediction and the conserved amino acids in Nipsnap1CT, I made a series of double mutants targeting Y190A/K191A, E199A&W200A,
G219K/F221V, I225K/G226K, and H233L/W235L (Figure 19). Mutagenic primers (Table
4) were designed to replace conserved amino acids with non- preferred NAD-interacting
residues such as Ala, Glu, Leu, and Lys (Ansari and Raghava 2010).
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Figure 19 The conserved C-terminal region of Nipsnap1 interacts with both NAD and ATP at specific amino acid residues.
Sequence alignment of the C-terminal Nipsnap domain containing proteins from mouse (NIP1-C) and Agrobacteria (IVQY and
IVQS) from Uniprot, showing conservation in the C-terminal region. The conserved residues that were mutated and examined in
biochemical pull-down assays are shown in green.
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Mutagenic constructs restriction enzyme digestion
After performing site-directed mutagenesis and replacing the targeted amino acids,
XL1-Blue cells were transformed with mutant constructs. pWhitescript mutagenesis
control plasmid was used to test the efficiency of mutant plasmid in this site-directed
mutagenesis experiment. The oligonucleotide control primer 1 and 2 create a point
mutation on the pWhitescript 4.5-kb control plasmid and produce glutamine codon (CAA)
result in β-galactosidase activity. XL1-Blue supercompetent cells transformed with this
pWhitescript 4.5-kb control plasmid with the β-galactosidase activity appear as blue
colonies on media containing IPTG and X-gal (Figure 20a). As explained in methods, prior
to transformation of XL1-Blue, the mutant plasmids were digested with DpnI to remove
the parental DNA containing WT methylated sequence. This step increases the efficiency
of mutagenesis procedure.

a

b

c

Figure 20 XL1-Blue supercompetent cells transfected with mutant plasmids on
agar plates. a) pWhitescript mutagenesis control appear blue on agar plate containing
ampicillin, 80 μg/ml X-gal and 20 mM IPTG. b) G219K/F221V colonies on LBampicillin agar plate c) H233L/W235L colonies on LB-ampicillin agar plate.
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Prior to sending the mutant constructs for sequencing, restriction enzyme digestion
(XhoI and HindIII) was performed to verify the correct insertion (Figure 21).

Figure 21 Restriction Enzyme Digestion. Plasmids were digested with XhoI and
HindIII restriction enzymes. The black-hollow arrow shows circular and uncut Nipsnap1
DNA inserted in pcDNA3 which was not treated with XhoI or HindIII. The blue-hollow
arrow shows linear Nipsnap1 DNA inserted in pcDNA3 that was cut at one restriction
enzyme site. The blue arrow indicates pcDNA3 without Nipsnap1 DNA. The black
arrow indicates Nipsnap1 DNA that was cut from pcDNA3 by XhoI and HindIII
restriction enzymes.
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Mutagenic constructs sequences
Finally, mutant plasmids were sent for sequencing at GENEWIZ (NJ, USA) to
verify we have the designed mutation, and no other unintentional changes. All mutant
plasmids

Y190A/K191A,

E199A/W200A,

G219K/F221V,

I225K/G226K,

and

H233L/W235L were confirmed by Sanger sequencing followed by alignments with
Nipsnap1 WT sequence using SerialCloner 2.6.1 software (Appendix Figures 27-31).

Nipsnap1-CT mutants significantly disrupt NAD binding.
To determine the amino acid residues that are involved in NAD binding, pull-down
assays were performed using lysates of HEK293T cells transiently transfected with HATagged mutant Nipsnap1 constructs. We found that Nipsnap1 double mutants
Y190A/K191A (in β1 strand), E199A/W200A (α1 helix), G219K/F221V (β2 strand), and
I225K/G226K (β2 strand) significantly (p<0.05, student’s t-test) disrupted Nipsnap1-NAD
interaction approximately by 40%, 20%, 50%, and 40%, respectively (Figure 22). In
contrast, double mutant H233L/W235L located in β3 strand did not have a significant
effect on NAD interaction (Figure 22).
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Figure 22 Mutations in conserved C-terminal region of Nipsnap1 disrupt NAD
interaction. NAD pull down was performed in HEK293 cells transiently transfected
with mutant Nipsnap1-HA constructs. Double mutant I225K/G226K, G219K/F221V,
Y190A/K191A, and E199A/W200A significantly decrease NAD interaction. Means ±
SEM, paired two-tailed T test and n=3 (IB; Immunoblotting, PD; Pull-down, WT: wild
type, KD; knock-down, black arrow shows Nipsnap1 band).
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Mutants Y190A/K191A and G219K/F221V significantly decreased Nipsnap1-ATP
interaction
In the next step, we investigated whether the same residues were involved in
binding to both NAD and ATP. Separopore-ATP pull-down experiments were performed
using lysates from HEK293T cells transiently transfected with HA-Tagged mutant
Nipsnap1 constructs. Double mutants Y190A/K191A and G219K/F221V significantly
decreased Nipsnap1-ATP binding, similar to Nipsnap1-NAD binding. Interestingly,
double mutant E199A/W200A increased the interaction between ATP and Nipsnap1
(approximately 50%) (Figure 23). This result suggests that E199/W200 residues may be
specifically involved in binding to the nicotinamide ring of NAD and in the absence of this
interaction, the Nipsnap1 binding pocket is more available to bind to ATP.
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Figure 23 The conserved C-terminal region of Nipsnap1 interacts with ATP at
specific amino acid residues. ATP pull down was performed in HEK293 cells
transiently transfected with mutant Nipsnap1-HA constructs. Double mutant
G219K/F221V, and Y190A/K191A significantly decreased ATP interaction. However,
double mutant E199A/W200A significantly increased ATP interaction. Means ± SEM,
paired two-tailed T test and n=3 (IB; Immunoblotting, PD; Pull-down, WT: wild type,
KD; knock-down, black arrow shows Nipsnap1 band.
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Refinement of the Nipsnap1 binding pocket
To determine if the residues identified in the mutation experiments participated in
a binding pocket for NAD and ATP, we performed ligand docking simulations (Figure 24).
The structure of the C-terminal region of Nipsnap1 was modeled using the Phyre2 protein
modeling web server (Kelley et al. 2015).

Using a ‘blind docking’ approach with

AutoDock Vina (Trott and Olson 2009), NADH, NAD+, ATP and ADP were individually
docked with the C-terminal region of Nipsnap1. The residues that were commonly close to
each ligand in low-energy docked conformations were examined (Table 7). Tyr190 was
the top ranked residue with respect to binding to NADH, NAD+, ATP and ADP (Table 7).
This result was consistent with the biochemical pull-down experiments showing that
mutation of Y190 disrupted binding of full-length Nipsnap1 to NAD and ATP (Figure 22
and 23). However, the docking simulations did not identify E199 or W200 to have any
significant interactions with any of the ligands, particularly the nicotinamide ring of NAD.
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Table 7 Nipsnap1 residues close to ligands in docking simulations.
Rank of residue* for docking with:
Residue

NADH

NAD+

ATP

ADP

Average

Tyr190 (8)

2

2

4

1

2.25

Arg247 (65)

4

1

3

2

2.5

Arg211 (29)

1

5

1

4

2.75

Arg188 (6)

5

4

2

3

3.5

Trp251 (69)

3

3

6

5

4.25

His233 (51)

7

7

5

6

6.25

Trp256 (74)

8

6

8

7

7.25

Val260 (78)

11

9

9

10

9.75

Trp204 (22)

9

11

12

9

10.25

Trp235 (53)

6

15

10

11

10.5

The number in parenthesis correspond to the residue on the C-terminal region using for
modeling and docking simulations. * The rank of residue was determined from the
Boltzmann weighted distance between the ligand and the residue averaged over the 10
lowest energy docking poses, where 1 is the residue that had the lowest average distance
to the ligand.
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Figure 24 Predicted structure of Nipsnap1 C-terminal domain. Residues that were
most commonly close to the ligands in low energy docked conformations and form the
binding pocket are shown as sticks. R188 and Y190 are shown in blue, R211 is blue-green,
H233 in green, and R247 and W251 are yellow.

4. Discussion
In his chapter, we gained significant insights into the function of the highly
conserved Nipsnap1 domain. Using a computational approach (protein structure modeling
and virtual ligand screening) we predicted that NADH and NADPH were the top two
ranked ligands that most likely will bind to Nipsnap1. This prediction was confirmed using
pull down assays. Interestingly, we found that Nipsnap1 binds to ATP in addition to NAD
and NADP. Therefore, we performed mutation analysis to map the residues that are
involved in Nipsnap1 ligand binding. Importantly, we found that both NAD and ATP bind
to the same site in the C-terminal region of Nipsnap1. This finding is significant and novel
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suggesting that Nipsnap1 might have a dual specificity binding pocket in its C-terminal. A
recent study has shown that ATP has a dual regulatory function on the αγ heterodimer of
NAD-dependent isocitrate dehydrogenase (NAD-IDH) (Sun et al. 2020). They showed that
low concentration of ATP bound to allosteric site of NAD-IDH and activated the protein.
On the other hand, high concentration of ATP competed with NAD for binding to the active
site and inhibited the NAD-IDH enzyme activity (Sun et al. 2020). However, our result
indicated while a low concentration of ATP does not have a significant effect on Nipsnap1NAD interaction, higher concentration of ATP (1mM) significantly increases this
interaction. In addition, our mutational analysis suggests that both ATP and NAD bind to
the same amino acid residues in the same binding pocket.
Based on mutation analysis and ligand docking, we determined that Y190 is critical
for binding to both NAD and ATP. This finding is similar to the previously described
scorpion motif, a Y-X10-Y motif which forms a 3D structure shaped like a scorpion (Lee
et al. 2010). The first three and last residues of scorpion motif interact typically with the
nicotinamide ring of NAD by Van der Waals forces (Lee et al. 2010). It is possible that
Y190-X10-W200 residues in NIPSANP1-CT forms a scorpion motif. Our mutation analysis
showed W200 (the second part of the scorpion motif) is also critical, but this was not
confirmed by the docking simulation. More detailed analysis of ligand docking would
require a crystal structure of the mammalian Nipsnap1. Our protein modeling and docking
simulations are based on a very distant bacterial crystal structure.
As mentioned in chapter I, upon depolarization of mitochondria, Nipsnap1 is
translocated to outer mitochondrial membrane and triggers mitophagy (Princely Abudu et
al. 2019). However, the exact mechanism of how Nipsnap1 detects the malfunction of the
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mitochondria to start mitophagy is unknown. Our finding that Nipsnap1 interacts with both
ATP and NAD could be critical and play an important role in terms of sensing and
triggering mitophagy. It has been shown that low levels of ATP and low levels of NADH
(high levels of NAD+) could trigger mitophagy (Fang 2019; Hwang and Hwang 2017).
Future experiments are needed to perform detailed affinity and kinetic binding studies to
determine if Nipsnap1 prefers to bind to NADH or NAD+. Similarly, we would need to
know if Nipsnap1 prefers to bind to ATP over ADP. These results would have implications
with respect to what Nipsnap1 is sensing and how it might trigger mitophagy.
Lastly, pulling it all together, it is plausible that if Nipsnap1 is an energy sensor,
then it would be tethered to PDH, which is a key regulator of mitochondrial OXPHOS
pathway. If PDH is not active, then the TCA cycle is not active because of low AcetylCoA, which in turn results in less NADH and ATP being produced in the mitochondria. If
a mitochondrion is not active, then it must be targeted for mitophagy. It is intriguing to
think that Nipsnap1 could be the mitochondrial health sensor and play a critical role in the
decision point for mitophagy.
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Chapter IV: Conclusion and future direction

Over the last two decades, Nipsnaps have been implicated in different physiologic
and pathologic conditions. Recent evidence shows that Nipsnap1 and Nipsnap2 are critical
mediators of mitophagy by recruiting PARKIN and other mitophagy proteins (Princely
Abudu et al. 2019). Implication of Nipsnaps in PINK1-PRKN mediated mitophagy is
significant because it can generally explain their role in many of the seemingly disparate
physiological or pathological associations that have been documented. It is not clear if
mitophagy is the only role for Nipsnap proteins or if they have other critical functions by
virtue of their interaction with PDH and BCKA complexes (Nautiyal et al. 2010; Islam et
al. 2010). Moreover, the precise role of the highly conserved Nipsnap domain has not been
investigated with respect to regulation of mitophagy or PDH activity. To address these
issues, in this study, I investigated the effect of Nipanap1 on PDH activity and protein
levels. In addition, I characterized the ligand binding properties of the conserved Nipsnap
domain.
Based on the results presented in chapter II, Nipsnap1 does not appear to affect
PDH enzyme activity or protein levels in transiently transfected HEK293 cells, and in brain
and liver tissues of Nipsnap1 KD mice. Therefore, we propose that Nipsnap1 interaction
with PDH may serve to localize Nipsnap1 to PDH, which is a critical enzyme complex that
connects cytosolic glycolysis pathway to mitochondrial TCA cycle. This interaction may
be important in localizing Nipsnap1 to inner mitochondrial membrane and in proximity to
the major switch point between glycolysis and oxidative phosphorylation.
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Figure 25 Working model for NAD+ and ATP interaction to the same binding
pocket in Nipsnap1. We hypothesize that Nipsnap1-ATP interaction keeps Nipsnap1
tethered to PDH in healthy mitochondria (left panel). However, in unhealthy
mitochondria, where NAD+ levels increase and ATP levels drop, NAD+ replaces ATP
in the Nipsnap1 binding pocket. The Nipsnap1-NAD interaction causes a conformational
change in Nipsnap1 to release from PDH and to translocate to the outer mitochondrial
membrane (right panel).

In Chapter III, using biochemical assays and mutation analysis, I showed that both
NAD+ and ATP bind to the same binding pocket in the C-Terminal domain of Nipsnap1.
Nipsnap1 prefers to bind to NAD+ over ATP at lower concentrations. However, the
concentration of ATP is approximately 10 times higher than NAD+ in the healthy
mitochondria (Feher 2017). Therefore, it is plausible that Nipsnap1 is bound to ATP in
healthy mitochondria, which might prevent Nipsnap1 translocation to outer mitochondrial
membrane (Figure 25). However, in unhealthy mitochondria where ATP levels drop
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significantly and NAD+ level increase, Nipsnap1 would release ATP and bind to NAD+.
We propose that NAD+ binding would produce a conformational change in Nipsnap1 and
result in translocation of Nipsnap1 to outer mitochondrial membrane to initiate of
mitophagy (Figure 26). The NAD+/NADH ratio plays a critical role in mitochondrial
health (Hwang and Hwang 2017). Increased level of NAD+ improves mitochondrial quality
through restoring mitophagy and elimination of damaged mitochondria (Fang et al. 2019;
Hwang and Hwang 2017). Therefore, our results provide new insights into the potential
mechanism by which Nipsnap1 senses mitochondrial damage and triggers mitophagy.
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Figure 26 Nipsnaps may be involved in neurodegeneration by sensing
mitochondrial health and regulating mitophagy. In response to metabolic stress,
Nipsnap1 triggers mitophagy via recruitment of PARKIN to remove damaged
mitochondria. They may sense the metabolic state of mitochondria via direct interaction
with pyruvate dehydrogenase and NAD+. Deficits in Nipsnaps (asterisk) could interfere
with mitophagy and result in a variety of pathological conditions. We hypothesize that
Nipsnap1 could contribute to pathogenesis of Alzheimer’s Disease via its interaction
with amyloid precursor protein intracellular domain (AICD), possibly through
interfering with Nipsnap1-PARKIN interaction.

Mitophagy is important to maintain cellular homeostasis by removing damaged
mitochondria. Under normal conditions, metabolic stress and mitochondrial damage
induce Nipsnap1 translocation to the outer mitochondrial membrane to trigger mitophagy
via a PARKIN-dependent pathway (Princely Abudu et al. 2019). We propose that
dysfunctional Nipsnap1 might therefore underlie some neurodegenerative diseases (Figure
26). Under metabolic stress, dysfunctional Nipsnap1 may not be able to detect NAD+
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levels and remains tethered to PDH complex, resulting in accumulation of damaged
mitochondria. In addition, our group previously showed that Nipsnap1 interacts with AICD
(Tummala et al. 2010). Therefore, another mechanism by which Nipsnap1 could be
involved in neurodegeneration associated with AD, is that the AICD interaction with
Nipsnap1 disrupts its ability to interact with PARKIN and trigger mitophagy (Figure 26).
Taken together, this work has identified a critical role for the highly conserved
Nipsnap1 domain and has set the stage to investigate its mechanistic role in sensing
mitochondrial damage and possible role in pathogenesis of a variety of neurodegenerative
conditions such as Parkinson’s and Alzheimer’s diseases.
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Features [Seq_1; Nipsnap1_HA]:
Mitochondrial signal seq

: [7 : 75]

HindIII

: [1 : 6]

Epitope

: [424 : 471]

XhoI

: [859 : 864]

HA Tag

: [868 : 894]

Features [Seq_2; Y190A/K191A ]:
Mitochondrial signal seq

: [7 : 75]

HindIII

: [1 : 6]

Epitope

: [424 : 471]

Mutation Y190A/K191A

: [572 : 578]

XhoI

: [859 : 864]

HA tag

: [868 : 894]

Figure 27 Alignment of Sequence_1: [Nipsnap1_HA.xdna] with Sequence_2: [Mutant
Y190A/K191A .xdna]. Similarity: 890/894 (99.55 %). As shown above 190 and 191
amino acids were successfully replaced when it was compared with Nipsnap1 HA as
control. The alignment was performed using SerialCloner 2.6.1 software.
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Features [Seq_1; Nipsnap1_HA]:
Mitochondrial signal seq

: [7 : 75]

HindIII

: [1 : 6]

Epitope

: [424 : 471]

XhoI

: [859 : 864]

HA Tag

: [868 : 894]

Features [Seq_2; E199A&W200A]:
Mitochondrial signal seq

: [7 : 75]

HindIII

: [1 : 6]

Epitope

: [424 : 471]

Mutation E199A/W200A

: [601 : 606]

XhoI

: [864 : 859]

HA Tag

: [868 : 894]

Figure 28 Alignment of Sequence_1: [Nipsnap1_HA.xdna] with Sequence_2: [Mutant
E199A/W200A.xdna]. Similarity: 891/894 (99.66 %). As shown above 199 and 200
amino acids were successfully replaced when it was compared with Nipsnap1 HA as
control. The alignment was performed using SerialCloner 2.6.1 software.
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||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CTGCTGTCCAGGAGAAACCAGTTGCTTCTGGAGTTCAGCTTCTGGAATGAGCCACAGCCC

540

CGAGCTGGCCCCAATATCTATGAGCTGAGGACATATAAACTCAAGCCAGGAACCATGATT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CGAGCTGGCCCCAATATCTATGAGCTGAGGACATATAAACTCAAGCCAGGAACCATGATT

600

GAATGGGGAAACAACTGGGCTCGGGCCATCAAGTACCGTCAGGAGAACCAGGAGGCGGTG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GAATGGGGAAACAACTGGGCTCGGGCCATCAAGTACCGTCAGGAGAACCAGGAGGCGGTG

660

GG-AGGCTTCTTTTCACAAATAGGAGAGCTCTACGTGGTACACCACTTATGGGCCTACAA
|||| ||||||||||||||||||||||||||||||||||||||||||||||||||||
-AAAGGCGTCTTTTCACAAATAGGAGAGCTCTACGTGGTACACCACTTATGGGCCTACAA

719

360

420

480

540

600

660

719

AGATTTGCAATCTCGGGAGGAGACTCGAAATGCGGCCTGGAGAAAGAGGGGCTGGGATGA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AGATTTGCAATCTCGGGAGGAGACTCGAAATGCGGCCTGGAGAAAGAGGGGCTGGGATGA

779

AAATGTCTACTACACAGTCCCCTTGGTTCGACACATGGAGTCACGAATCATGATTCCTCT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AAATGTCTACTACACAGTCCCCTTGGTTCGACACATGGAGTCACGAATCATGATTCCTCT

839

GAAGATTTCTCCTCTCCAGCTCGAGATGTACCCATACGATGTTCCAGATTACGCT
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
GAAGATTTCTCCTCTCCAGCTCGAGATGTACCCATACGATGTTCCAGATTACGCT

Features [Nipsnap1_HA]:
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894

779

839

Features [Nipsnap1_HA]:
Mitochondrial Signal Seq

: [7 : 75]

XhoI

: [859 : 864]

HindIII

: [1 : 6]

Epitope

: [424 : 471]

HA Tag

: [868 : 894]

Features [Seq_2; G219K/F221V]:
Mitochondrial Signal Seq

: [7 : 75]

XhoI

: [859 : 864]

HindIII

: [1 : 6]

Mutant

: [660 : 667]

Epitope

: [424 : 471]

HA Tag

: [868 : 894]

Figure 29 Alignment of Sequence_1: [Nipsnap1_HA.xdna] with Sequence_2: [Mutant
G219K/F221V.xdna]. Similarity: 891/894 (99.66 %). As shown above 219 and 221 amino
acids were successfully replaced when it was compared with Nipsnap1 HA as control. The
alignment was performed using SerialCloner 2.6.1 software.
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AAGCTTATGGCTCCGCGGTTGTGCATCATCTCTGCAGCGGCACGGCGGCTATTCACGAAG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AAGCTTATGGCTCCGCGGTTGTGCATCATCTCTGCAGCGGCACGGCGGCTATTCACGAAG

60

CCGAGACCCCGTGCTGGGGACCTCGCGGCTGCGGGTGCTGTGCGCTTCTATTCCAAGGAC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CCGAGACCCCGTGCTGGGGACCTCGCGGCTGCGGGTGCTGTGCGCTTCTATTCCAAGGAC

120

AGTGAAGGAAGCTGGTTCCGTTCCCTCTTTGTCCACAAGGTGGATCCTCGGAAGGACGCC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AGTGAAGGAAGCTGGTTCCGTTCCCTCTTTGTCCACAAGGTGGATCCTCGGAAGGACGCC

180

CACTCCACTCTGCTGTCCAAGAAGGAGACTAGTAATCTCTACAAGATCCAGTTTCACAAC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CACTCCACTCTGCTGTCCAAGAAGGAGACTAGTAATCTCTACAAGATCCAGTTTCACAAC

240

GTGAAGCCCGAATGTCTGGATGCCTACAACAGTCTGACGGAGGCTGTACTGCCCAAGCTG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GTGAAGCCCGAATGTCTGGATGCCTACAACAGTCTGACGGAGGCTGTACTGCCCAAGCTG

300

CACCTGGATGAGGACTATCCCTGCTCGCTTGTGGGCAACTGGAACACGTGGTACGGGGAG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CACCTGGATGAGGACTATCCCTGCTCGCTTGTGGGCAACTGGAACACGTGGTACGGGGAG

360

CAGGACCAGGCGGTACACCTATGGCGGTTCTCAGGTGGCTACCCGGCCCTCATGGACTGC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CAGGACCAGGCGGTACACCTATGGCGGTTCTCAGGTGGCTACCCGGCCCTCATGGACTGC

420

ATGAACAAGCTAAAAAACAACAAGGAGTACCTGGAGTTCCGGAAGGAACGGAGCAAGATG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ATGAACAAGCTAAAAAACAACAAGGAGTACCTGGAGTTCCGGAAGGAACGGAGCAAGATG

480

CTGCTGTCCAGGAGAAACCAGTTGCTTCTGGAGTTCAGCTTCTGGAATGAGCCACAGCCC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CTGCTGTCCAGGAGAAACCAGTTGCTTCTGGAGTTCAGCTTCTGGAATGAGCCACAGCCC

540

CGAGCTGGCCCCAATATCTATGAGCTGAGGACATATAAACTCAAGCCAGGAACCATGATT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CGAGCTGGCCCCAATATCTATGAGCTGAGGACATATAAACTCAAGCCAGGAACCATGATT

600

GAATGGGGAAACAACTGGGCTCGGGCCATCAAGTACCGTCAGGAGAACCAGGAGGCGGTG
|||||||||||||||||||||||||||||||||||||||||||||||||||||:||||||
GAATGGGGAAACAACTGGGCTCGGGCCATCAAGTACCGTCAGGAGAACCAGGANGCGGTG

660

GGAGGCTTCTTTTCACAAAT-AGGAGAGCTCTACGTGGTACACCACTTATGGGCCTACAA
||||||||||||||||||| | ||||||||||||||||||||||||||||||||||||
GGAGGCTTCTTTTCACAAAAAAA-AGAGCTCTACGTGGTACACCACTTATGGGCCTACAA

719

AGATTTGCAATCTCGGGAGGAGACTCGAAATGCGGCCTGGAGAAAGAGGGGCTGGGATGA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AGATTTGCAATCTCGGGAGGAGACTCGAAATGCGGCCTGGAGAAAGAGGGGCTGGGATGA

779

AAATGTCTACTACACAGTCCCCTTGGTTCGACACATGGAGTCACGAATCATGATTCCTCT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AAATGTCTACTACACAGTCCCCTTGGTTCGACACATGGAGTCACGAATCATGATTCCTCT

839

GAAGATTTCTCCTCTCCAGCTCGAGATGTACCCATACGATGTTCCAGATTACGCT
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
GAAGATTTCTCCTCTCCAGCTCGAGATGTACCCATACGATGTTCCAGATTACGCT
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Features [Seq_1; Nipsnap1_HA]:
Mitochondrial signal seq

: [7 : 75]

HindIII

: [1 : 6]

Epitope

: [424 : 471]

XhoI

: [859 : 864]

HA Tag

: [868 : 894]

Features [Seq_2; I225K/G226K]:
Mitochondrial Signal Seq

: [7 : 75]

HinIII

: [1 : 6]

Epitop

: [424 : 471]

Mutant I225K/G226K

: [677 : 684]

XhoI

: [859 : 864]

HA Tag

: [868 : 894]

Figure 30 Alignment of Sequence_1: [Nipsnap1_HA.xdna] with Sequence_2: [Mutant
I225K/G226K.xdna]. Similarity: 891/894 (99.66 %). As shown above 225 and 226 amino
acids were successfully replaced when it was compared with Nipsnap1 HA as control. The
alignment was performed using SerialCloner 2.6.1 software.
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AAGCTTATGGCTCCGCGGTTGTGCATCATCTCTGCAGCGGCACGGCGGCTATTCACGAAG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AAGCTTATGGCTCCGCGGTTGTGCATCATCTCTGCAGCGGCACGGCGGCTATTCACGAAG

60

CCGAGACCCCGTGCTGGGGACCTCGCGGCTGCGGGTGCTGTGCGCTTCTATTCCAAGGAC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CCGAGACCCCGTGCTGGGGACCTCGCGGCTGCGGGTGCTGTGCGCTTCTATTCCAAGGAC

120

AGTGAAGGAAGCTGGTTCCGTTCCCTCTTTGTCCACAAGGTGGATCCTCGGAAGGACGCC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AGTGAAGGAAGCTGGTTCCGTTCCCTCTTTGTCCACAAGGTGGATCCTCGGAAGGACGCC
CACTCCACTCTGCTGTCCAAGAAGGAGACTAGTAATCTCTACAAGATCCAGTTTCACAAC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CACTCCACTCTGCTGTCCAAGAAGGAGACTAGTAATCTCTACAAGATCCAGTTTCACAAC
GTGAAGCCCGAATGTCTGGATGCCTACAACAGTCTGACGGAGGCTGTACTGCCCAAGCTG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GTGAAGCCCGAATGTCTGGATGCCTACAACAGTCTGACGGAGGCTGTACTGCCCAAGCTG
CACCTGGATGAGGACTATCCCTGCTCGCTTGTGGGCAACTGGAACACGTGGTACGGGGAG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CACCTGGATGAGGACTATCCCTGCTCGCTTGTGGGCAACTGGAACACGTGGTACGGGGAG

60

120
180
180
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240
300
300
360
360

CAGGACCAGGCGGTACACCTATGGCGGTTCTCAGGTGGCTACCCGGCCCTCATGGACTGC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CAGGACCAGGCGGTACACCTATGGCGGTTCTCAGGTGGCTACCCGGCCCTCATGGACTGC

420

ATGAACAAGCTAAAAAACAACAAGGAGTACCTGGAGTTCCGGAAGGAACGGAGCAAGATG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ATGAACAAGCTAAAAAACAACAAGGAGTACCTGGAGTTCCGGAAGGAACGGAGCAAGATG

480

CTGCTGTCCAGGAGAAACCAGTTGCTTCTGGAGTTCAGCTTCTGGAATGAGCCACAGCCC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CTGCTGTCCAGGAGAAACCAGTTGCTTCTGGAGTTCAGCTTCTGGAATGAGCCACAGCCC

540

CGAGCTGGCCCCAATATCTATGAGCTGAGGACATATAAACTCAAGCCAGGAACCATGATT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CGAGCTGGCCCCAATATCTATGAGCTGAGGACATATAAACTCAAGCCAGGAACCATGATT

600

GAATGGGGAAACAACTGGGCTCGGGCCATCAAGTACCGTCAGGAGAACCAGGAGGCGGTG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GAATGGGGAAACAACTGGGCTCGGGCCATCAAGTACCGTCAGGAGAACCAGGAGGCGGTG

660

GGAGGCTTCTTTTCACAAATAGGAGAGCTCTACGTGGTACACCACTTATGGGCCTACAAA
||||||||||||||||||||||||||||||||||||||||||| ||||| ||||||||||
GGAGGCTTCTTTTCACAAATAGGAGAGCTCTACGTGGTACACCTCTTATTGGCCTACAAA

720

GATTTGCAATCTCGGGAGGAGACTCGAAATGCGGCCTGGAGAAAGAGGGGCTGGGATGAA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GATTTGCAATCTCGGGAGGAGACTCGAAATGCGGCCTGGAGAAAGAGGGGCTGGGATGAA

780

AATGTCTACTACACAGTCCCCTTGGTTCGACACATGGAGTCACGAATCATGATTCCTCTG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AATGTCTACTACACAGTCCCCTTGGTTCGACACATGGAGTCACGAATCATGATTCCTCTG

840

AAGATTTCTCCTCTCCAGCTCGAGATGTACCCATACGATGTTCCAGATTACGCT
||||||||||||||||||||||||||||||||||||||||||||||||||||||
AAGATTTCTCCTCTCCAGCTCGAGATGTACCCATACGATGTTCCAGATTACGCT
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Features [Seq_1; Nipsnap1_HA]:
Mitochondrial signal seq

: [7 : 75]

HindIII

: [1 : 6]

Epitope

: [424 : 471]

XhoI

: [859 : 864]

HA Tag

: [868 : 894]

Features [Seq_2; H233L/W235L]:
Mitochondrial signal seq

: [7 : 75]

HindIII

: [1 : 6]

Epitope

: [424 : 470]

Mutant H233L/W235L

: [704 : 710]

XhoI

: [859 : 864]

HA Tag

: [868 : 894]

Figure 31 Alignment of Sequence_1: [Nipsnap1_HA.xdna] with Sequence_2: [Mutant
H233L/W235L.xdna]. Similarity: 892/894 (99.78 %). As shown above 233 and 235
amino acids were successfully replaced when it was compared with Nipsnap1 HA as
control. The alignment was performed using SerialCloner 2.6.1 software.
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